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 Abstract  
 
 
This dissertation is an overview on the functionalization of known anticancer compounds 
in order to form different drug-conjugates able to self-assemble in water to form 
nanoparticles. This approach is useful to improve the drug delivery properties and 
pharmacokinetic profile of anticancer drugs. 
All the described conjugates, except for the ones illustrated in chapter 5, have the same 
general structure: the anticancer drug is connected to the self-assembly inducer trough a 
linker (Figure 1).  
 
Figure 1. General structure of the conjugates. 
 
Chapter 1 regards a general introduction about nanomedicine, the advantages of the 
use of nanotechnology-based systems in cancer treatment and the benefits of nano-
formulated drugs in the improvement of drug-delivery. Furthermore, nanoparticles are 
presented with a focus on their classification, characterization and preparation 
techniques.  
Chapter 2 regards the preparation of different types of self-assembled nanoparticles 
using various anticancer compounds and dyes but with the same lipophilic tail as self-
assembling inducer: squalene. Different natural anticancer compounds such as paclitaxel, 
cyclopamine and doxorubicin and dyes, as fluorescein and tetramethylrhodamine, were 
functionalized to obtain squalene-based conjugates. Both hetero-nanoparticles composed 
by two drug-conjugates and drug- and dye-conjugates were prepared and tested. 
Chapter 3 is focused on the importance of the self-assembly inducer and describes the 
preparation of new conjugates containing an active moiety as self-assembly inducer. In 
particular, in this section, is described the preparation of conjugates composed by aloin or 
podophyllotoxin as active compounds and 4-(1,2-diphenylbut-1-en-1-yl) aniline, an analog 
of the know anticancer compound tamoxifen, as self-assembly inducer.  
  
Chapter 4 highlights the influence of the linker between the active compound and the 
self-assembly inducer to obtain an effective release of the free drug. In particular, it is 
described the synthesis of a new self-immolative linker able to trigger the drug release in 
particular conditions, specifically in the presence of a lipase. This linker was used for the 
preparation of two conjugates containing the known anticancer compound N-
desacetylthiocolchicine. 
Chapter 5 concerns the preparation of dual drug-conjugates able to form 
nanoparticles without the presence of a self-assembly inducer. These conjugates have a 
symmetrical structure: two molecules of the same drug are linked by a chain able to 
guarantee the drug release in particular conditions (Figure 2). The natural anticancer 
compounds involved in the preparation of this type of conjugates are paclitaxel, 
epothilone A, podophyllotoxin and camptothecin and the linker used contain a disulfide 
moiety able to be cleaved in cellular environment. 
 
 
Figure 2. General structure of the conjugates. 
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1.1 Nanomedicine 
 
In the last decades, nanotechnology systems have been extensively studied and 
remarkable progresses have been made in the field of imaging and cancer therapy.1 
Currently the most advanced area of nanomedicine is the development of nanoparticles 
for drug delivery because nanotechnology-based systems offer the possibility to improve 
a personalized treatment of disease.2  
Nanomedicine are defined as systems that incorporate nanoparticles (1-100 nm) 
containing adsorbed, encapsulated, dispersed, or conjugated drugs or imaging agents. 
The numerous benefits to overcome the limitations of conventional formulations and the 
promising progresses both in cancer diagnosis and treatment make nanomedicine being 
enthusiastically evaluated and deeply studied. Indeed, Food and Drug Administration 
(FDA) have recently approved many nanodrug products and they are now on the market 
(Table 1). 
 
Limitation of traditional chemotherapy 
Many anticancer drugs commonly used in clinical practice often show, in addition to a 
high cytotoxic activity, some toxic side effects. These side effects sometimes force 
treatment delay and dose reduction. Furthermore, traditional chemotherapeutic agents 
remain in the circulation for short periods making the therapy ineffective. The therapeutic 
window of drugs can be limited by the lack of selectivity against cancer cells and their 
ability to reach the site of action is partially compromised by a poor solubility that make 
them unable to penetrate biological barriers.3  In addition, metabolization and 
degradation phenomena contribute to decrease the drug concentration at the biological 
target.4 Drug accumulation inside the tumor is also prevented by the action of P-
glycoprotein, a multidrug resistance protein overexpressed on the membrane of cancer 
cells, which act as efflux pump.5 
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Drug delivery systems Stage of 
development 
Examples 
of application 
References 
Liposomes Marketed Amphotericin B 
Daunorubicin  
Doxorubicin 
[6] 
[7] 
[8] 
Micelles    
Phospholipid Preclinical Paclitaxel  
Camptothecin  
Diazepam 
[9] 
[10] 
[11] 
Pluronic® Clinical 
Preclinical 
Doxorubicin 
Paclitaxel  
Tamoxifen 
Etoposide 
[12] 
[13] 
[14] 
[15] 
Poly (L-aminoacid) Clinical  
In vitro  
Doxorubicin  
Antisense oligonucleotides 
[16,17] 
[18] 
Polyester  
 
Preclinical Paclitaxel 
Doxorubicin 
[19] 
[20,21] 
Nanoemulsions  
 
Preclinical Amphotericin B  
Paclitaxel  
Dexamethasone  
Benzathine penicillin G  
[22] 
[23] 
[24] 
[25] 
Nanoparticulate systems    
Drug nanocrystals  
 
Preclinical Amphotericin B 
Etoposide, camptothecin, paclitaxel 
[26] 
[27] 
Polymer-based 
nanoparticles  
 
Preclinical Tamoxifen  
Cyclosporin-A  
Theophylline 
[28] 
[29] 
[30] 
Lipid-based nanoparticles  
 
Preclinical Doxoribicin  
Camptothecin 
[31] 
[32] 
Albumin nanoparticles  
 
Marketed  
In vitro 
Paclitaxel  
DNA and antisense oligonucleotides 
[33] 
[34,35] 
Nanogels  Preclinical Oligonucleotides [36] 
Dendrimers  
 
 
Preclinical 
In vitro 
 
Indometacin 
5-fluorouracil  
Antisense oligonucleotides 
[37] 
[38] 
[39] 
 
Table 1. Nanoscale systems for drug delivery. 
 
Nanotechnology in drug delivery 
The use of nanocarriers as drug delivery system for anticancer drugs can improve their 
overall pharmacological properties:  increasing in biodistribution and pharmacokinetic 
will result in improved efficacy of the drug.40,41 Nanobased systems have been also shown 
to improve the stability of a wide range of anticancer compounds as oligonucleotides, 
peptides or small molecules. Nanocarriers are often developed exploiting safe and 
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biocompatible materials in order to replace existing vehicles that may cause side effects.42 
Furthermore, side effects are reduced as a consequence of preferential accumulation at 
tumor sites that have permeable vasculature. The dose required for efficacy is then 
reduced thanks to selective targeting and decreased clearance.43,44 In addition, 
nanoformulated drugs can increase water solubility of hydrophobic chemotherapeutic 
agents allowing an efficient membrane permeation.45 The main advantages of nanocarrier 
formulation in medicine are reported in Figure 3. 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3. Advantages of nanocarrier formulation in medicine. 
 
 
Tumor targeting 
 
One of the main advantages of nanotechnology for cancer treatment is tumor targeting. 
The ability of nanomedicine to selectively target cancer cells and to differentiate tumor 
and healthy tissues is due to two fundamental processes: passive and active targeting. 
Passive targeting exploits the enhanced permeability and retention (EPR) effect46,47 to 
reach a higher concentration of nanoparticles in the tumor, while active targeting takes 
Nanocarriers 
Formulation 
of poorly water 
soluble active agents 
 
Elimination 
From the body intact 
or biodegradated form 
 
Targeting 
to a specific organ, 
tissue and cell type 
 
Multimodality 
for multimodal diagnostics 
and therapeutics 
 
Controlled release 
of incorporated  
active agents 
 
Protection 
of incorporated agents 
from degradation 
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advantage of selective molecular recognition of antigens, usually proteins, which are 
often overexpressed on cancer cells surface in order to selectively target tumor.48  
These two different processes of tumor cell targeting can be applied both independently 
or combined to get an increased outcome.49 
 
Passive targeting 
Passive targeting occurs due to nanoparticles extravasation in tumor tissue where the 
microvasculature is leaky. This feature of tumor vasculature is due to increased 
angiogenesis of the tumor and to the fact that cancer cells are not responsive to signaling 
for orderly vasculogenesis.50 
Most of solid tumors shows a vascular pore cutoff size of 100-780 nm,51,52 while healthy 
tissue vasculature is impermeable to carriers larger than 2-4 nm.53 Therefore, 
nanoparticles are able to increase drug concentration in target sites, by extravasation, 
and to significantly reduce drug accumulation and toxicity to healthy tissues. Moreover, 
nanoparticles circulating time in tumor tissue is longer respect to normal tissue because 
of reduced lymphatic clearance.54  
 
Active targeting 
In case of active targeting, nanodrugs are designed in order to preferentially interact with 
cancer cells. Indeed, tumor tissues have some unique features that discriminate them 
from normal cells. In particular, some receptors are overexpressed on the surface of 
cancerous cells and they can be used as targets.  
Active targeting is based on molecular recognition. Nanoparticles are functionalized with 
targeting agents and interact with tumor cells either by ligand-receptor interaction or 
antibody-antigen recognition.55,56,57 After recognition, nanoparticles are internalized in 
the cells, by receptor-mediated endocytosis or phagocytosis, allowing the drug to show 
its biological activity.58  
A wide variety of receptors, such as folate ligand,59,60 transferrin,61,62  death receptor (DR) 
complexes,63 epidermal growth factor receptor (EGFR),64 as well as tumor-specific 
antigens have been exploited to selectively target tumor tissues.  
Nanotechnology and cancer 
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Besides, nanoparticles have been functionalized with small molecules, monoclonal 
antibodies65 and nucleic acid aptamers66 to achieve active targeting by molecular 
recognition. Ligands can be attached to nanoparticles by covalent or non-covalent 
coupling. Non-covalent binding by physical association of targeting ligands to the 
nanocarrier has the advantage of eliminating the use of hard reaction conditions. 
However, there are potential problems, such as low and weak binding and poor control of 
the reactions. 
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1.2 Nanoparticles 
 
Following the IUPAC definition, we can define a nanoparticle as:  
"a particle of any shape with dimensions in the 1x10-9 and 1x10-7 m range. [...] Note 2: The 
basis of the 100- nm limit is the fact that novel properties that differentiate particles from 
the bulk material typically develop at a critical length scale of under 100 nm.  
Note 3: Because other phenomena (transparency or turbidity, ultrafiltration, stable 
dispersion, etc.) that extend the upper limit are occasionally considered, the use of the 
prefix nano is accepted for dimensions smaller than 500 nm.67 
 
Several types of nanoparticles are currently used for biological application and biomedical 
research (Figure 4).68 
 
 
 
 
 
 
 
Figure 4. Different types of nanoparticles. 
  
 Inorganic nanoparticles:  they are typically composed by inorganic material such 
as alumina, silica, metals, metal oxides and sulfides and they vary in size, shape 
and porosity. Porous inorganic nanoparticles provide a physical encasement to 
protect the molecular payload from degradation. They can also be engineered to 
evade the reticuloendothelial system by varying size and surface composition. 
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Many inorganic nanoparticles are currently used for biological applications: 
semiconductor quantum dots are commercially available as a viable alternative to 
fluorescently labelled particles while iron oxide nanoparticles have been 
approved for human use in magnetic resonance imaging applications as contrast 
enhancers.69 
 
 Polymeric nanoparticles: they are composed by polymers such as poly(ethylene 
glycol) (PEG), polylactic acid, polyglycolic acid, poly(methylmethacrilate), poly 
(butyl)cyano acrilate, polylactide (PLA) and poly(-lactide-co-glycolide) (PLGA). 
They are usually biodegradable and biocompatible and they offer a good 
potential for surface modification via chemical transformations. Polymerica 
nanoparticles are suitable for delivery of a wide range of therapeutic agents. The 
US FDA has approved biodegradable polymeric nanoparticles, such as PLA and 
PLGA, for human use. 
 
 Solid lipid nanoparticles: they are lipid-based colloidal systems characterized by a 
relatively rigid core consisting of hydrophobic lipids that are solid at room and 
body temperatures, surrounded by a monolayer of phospholipids. They are less 
toxic than polymeric or inorganic nanoparticles because of their ease of 
biodegradation. 
 
 Liposomes: they are concentric bilayered vesicles with an aqueous nucleus 
surrounded by a phospholipid membrane. Their amphiphilic nature, ease of 
surface modification, and good biocompatibility make them a good solution to 
increase the circulating half-life of proteins and peptides. Liposomes can adhere 
to cellular membranes to deliver a drug payload or transfer it by endocytosis. 
 
 Nanocrystals: they are aggregates of molecules that can be combined into a 
crystalline form of the drug surrounded by a thin coating of surfactant. The 
hydrophilic layer aids in the biological distribution and bioavailability, and 
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prevents aggregation of the crystalline drug material. These factors combine to 
increase the efficiency of overall drug delivery. Drawbacks are the requirement to 
crystalize the drug and the limited stability of nanocrystals. 
 
 Nanotubes: they are self-assembling sheets of atoms arranged in tubes and 
characterized by a large internal volume. The external surface can be easily 
functionalized. While they are potentially promising for pharmaceutical 
applications, human tolerance of these compounds remains unknown.  
  
 Dendrimers: they are polymer-based macromolecules formed from monomeric 
or oligomeric units, such that each layer of branching units doubles or triples the 
number of peripheral groups. The void area within a dendrimer, the extent of its 
branching, its ease of modification and preparation, and size control offer great 
potential for drug delivery. For example, water-soluble dendrimers may be 
designed with internal hydrophobicity, suitable for the incorporation of a 
hydrophobic drug. However, dendrimers require further improvement in 
cytotoxicity profiles, biocompatibility, and biodistribution. 
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1.3 Self-assembled Nanoparticles  
 
A  small  but  interesting  niche inside  anticancer  nanotechnology  is  represented  by  
nanosystems spontaneously  obtained  by  self-assembly  of  conjugates  composed of  
drugs  linked  to  a  proper  chemical  entity.70  The self-assembly  of drug  conjugates  into  
NPs  is  a  process  that  involves  the  formation of  an  ordered  structure  by  
spontaneous  organization  of  building blocks  as  a  consequence  of  specific  local  
interactions.  Assembly can  be  obtained  with  different  methods  and  conditions  but  
the  key role  of  the  amphilicity  of  the  components  is  often  fundamental. In  recent  
years,  the  use  of  drug  conjugates  to  obtain  NPs  has gained  considerable  
attention.71,72,73 These  conjugates  are  usually obtained  by  a  covalent  coupling  of  the  
drug  to  biocompatible lipid  moieties  and  the  resulting  molecules  are  able  to  form  
NPs  by self-assembly.  Self-assembly  is  a  process  that  is  mediated  by  noncovalent  
interactions  between  molecules  via  ionic  bonds,  H-bonding,  hydrophobic  interactions  
and  van  der  Waals  interactions.  Different organic  molecules,  such  as  biocompatible  
polymeric  chains  or endogenous  molecules  (terpenes  or  polysaccharides),  have  been 
used  as  self-assembly  inducers  by  covalent  linkage  to  drugs.  The drug  and  the  self-
assembly  inducer  can  be  directly  attached  or  can be  connected  by  a  linker,  which  
can  be  stable  in  serum  but  able  to release  the  drug  intracellularly. 
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1.4 Nanoparticles characterization 
 
Nanoparticles characterization is based on three main parameters: size, morphology and 
surface charge. These properties affect the physical stability and the in vivo distribution of 
the nanoparticles. 
Particle size 
 
The size of nanoparticles, including mean diameter and size distribution, influences their 
physical properties as well as biodistribution and retention in the body. It can be 
determined with different techniques. 
 Dinamic Light Scattering (DLS): it is used to determine the size of Brownian 
nanoparticles in colloidal suspensions in the nano and submicron ranges.  In this 
technique, a solution of spherical particles in Brownian motion causes a Doppler 
shift when exposed against shining monochromatic light (laser). This 
monochromatic light exposure hits the moving particle and it results in changing 
the wavelength of the incoming light. The extent of this change in wavelength 
determines the size of the particle.74  
 Scanning Electron Microscopy (SEM): it determines the size, shape and surface 
morphology with direct visualization of the nanoparticles. The sample is analysed 
by scanning with a focused beam of electrons and secondary electrons emitted 
from the sample surface determine the surface characteristic of the sample. 
Average mean size evaluated by SEM is comparable with results obtained by 
DLS.75 
 Transmission Electron Microscopy (TEM): it can provide imaging, diffraction and 
spectroscopic information of the nanoparticle. The surface characteristic of the 
sample are obtained by scanning the sample with a beam of electrons and 
analysing the transmitted beam.75 
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 Atomic Force Microscopy (AFM): it is based on a physical scanning of samples at 
sub-micron level using a probe tip of atomic scale. This technique offers a ultra-
high resolution in particle size measurement, with reported resolution on the 
order of fractions of a nanometre.76 
Surface charge 
 
Surface charge determines the interaction of nanoparticles with each others, with the 
biological environment as well as their electrostatic interaction with bioactive 
compounds. The stability of colloidal systems is usually analysed through the zeta 
potential of nanoparticles. Zeta potential is an indirect measure of the surface charge and 
it can be evaluated by analysing the potential difference between the outer Helmholtz 
plane and the surface of shear. High zeta potential (either positive or negative) are 
advantageous to ensure stability and avoid aggregation of the particles during storage.77 
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1.5 Nanoparticles Preparation  
 
A number of approaches have evolved for the preparation of nanoparticles, mainly 
relying on the composition, size, and shape of the nanoparticles to be prepared. Some 
common methods are discussed in detail below. 
 Solvent Evaporation Method: this method involves two steps. The first is the 
dissolution of the polymer/drug mixture in an organic solvent (as 
dichloromethane, chloroform or ethyl acetate) and the emulsification of the 
solution into an aqueous phase containing surfactant or emulsifying agents. The 
second step is the evaporation of the organic layer either by continuous stirring 
or by reducing the pressure, inducing polymer precipitation as nanospheres. Size 
range of nanoparticles was found to be influenced by the concentration and type 
of stabilizer, the polymer concentration and the homogenizer speed. 
Ultrasonication or high-speed homogenization may be often employed in order to 
produce small particle size.78 The nanoparticles are collected by 
ultracentrifugation and washed with distilled water to remove stabilizer residue 
or any free drug and lyophilized for storage.79 
 
 Salting Out Method: this method involves the separation of a water-miscible 
solvent from aqueous solution via a salting-out effect.80 The polymer and the drug 
are dissolved in an organic solvent, which is subsequently emulsified into an 
aqueous gel containing the salting out agent (electrolytes, such as magnesium 
chloride and calcium chloride, or non- electrolytes such as sucrose) and a colloidal 
stabilizer. This leads to the formation of oil/water emulsion which is further 
diluted with a certain volume of water or aqueous solution to enhance the 
diffusion of solvent into the aqueous phase, inducing the formation of 
nanospheres. Parameters such as stirring rate, internal/external phase ratio, 
concentration of polymers in the organic phase, type of electrolyte, concentration 
and type of stabilizer in the aqueous phase can be varied in this process.81  
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 Solvent Displacement/Precipitation Method: in this method, the molecule is 
dissolved in a semi-polar water miscible solvent, such as acetone or ethanol, and 
the solution is then poured or injected in an aqueous solution, either in the 
presence or absence of surfactant, under magnetic stirring. Nanoparticles are 
formed immediately by the rapid solvent diffusion, then the organic solvent is 
removed from the suspension under reduced pressure.82  
 
 Polymerization Method: this technique involves the polymerization of monomers 
to form nanoparticles in an aqueous solution. Ultracentrifugation can be used to 
purify nanoparticle suspension by removing various stabilizers and surfactants 
employed for polymerization, followed by the re-suspension of particles in an 
isotonic surfactant-free medium. 
 
 Production of Nanoparticles Using Supercritical Fluid Technology: Among the 
various processing techniques involving supercritical fluids, supercritical anti-
solvent (SAS) and rapid expansion of critical solution (RESS) are the most 
common. In the SAS technique, a liquid solvent, commonly methanol, is selected 
in order to be completely miscible with the supercritical fluid (CO2). The solute is 
dissolved in the organic layer and the extraction by the supercritical fluid leads to 
the instantaneous precipitation of the solute, since it is insoluble in the 
supercritical fluid, resulting in the formation of nanoparticles. In RESS method, 
the solute is dissolved in a supercritical fluid, such as supercritical methanol, and 
then the solution is rapidly expanded into a lower pressure region. This 
dramatically affects the solvent power of supercritical fluid, which is decreased, 
and the solute eventually precipitates.  
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2.1 Disulphide containing linker  
 
The concept of lipid-drug conjugates has gained considerable attention in recent years, 
and these conjugates are usually obtained by a covalent coupling of the drug to 
biocompatible lipid moieties. Among them, squalene, a natural precursor of many 
steroids, showed the ability, when linked to biologically active compounds, to achieve a 
spontaneous formation of nanoassemblies in water. Thus, squalene protects the drugs 
from environment damaging factors and, in some cases, also improves their 
pharmacokinetic profile by decreasing the toxicity of the associated drugs with an 
increase in their therapeutic index. This novel approach progressively extended its field of 
application from anticancer agents (gemcitabine, paclitaxel, cisplatin, 
doxorubicin)83,84,85,86,87,88 to antibiotics and from antiviral agents (penicillin, AZT, 
acyclovir)89,90 to nucleotides (siRNA).91,92 Furthermore, the ability to spontaneously 
nanoassemble allowed the preparation of nanoparticles containing both therapeutic and 
diagnostic agents.93,94 One of the key points in the realization of potent and efficient 
squalene prodrug resides in the release of the free drug; thus, the role of the linkage 
between the drug and the squalene moiety is crucial.  
In the last years our research group investigated the possibility to improve the biological 
activity of anticancer compounds by the preparation of squalene-incorporating 
derivatives with the use of a disulfide-containing linker to secure the drug release. It was 
prepared a novel class of disulfide-containing squalene conjugates (Scheme 1).  
 
 
 
Scheme 1. Supposed pathway for drug release of disulfide-containing squalene conjugates. 
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The presence of the squalene tail induces spontaneous self-assembly in water, while the 
disulfide bond induces drug release in the intracellular environment. Four known 
anticancer compounds were selected: paclitaxel, podophyllotoxin, camptothecin and 
epothilone A (Figure 5). These compounds are known to interact with tubulins (paclitaxel, 
podophyllotoxin and epothilone A) and with topoisomerase I (camptothecin), but they all 
suffer from many drawbacks, primarily due to the side effects associated with their low 
water solubility. The introduction of a lipophilic tail overcomes the problem by favouring 
the formation of nanoassemblies, more capable of membrane permeation.  
 
 
 
Figure 5. Structures of podophyllotoxin, paclitaxel, epothilone A and camptothecin. 
 
All the obtained compounds were effectively able to self-assemble in water to form 
nanoparticles and they were also able to release the parent drug in vitro. Disulfide-
containing paclitaxel squalene derivative showed a similar biological activity when 
compared to the parental drug. Immunofluorescence assay showed that this squalene 
conjugate enters A549 cells and stain microtubule bundles.  
The results described herein paved the way for different classes of squalene-based 
releasable nanoassemblies.95 
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2.2 Fluorescent hetero-nanoparticles 
 
The recent advances in nanotechnology and nanomaterials have been integrated into 
analytical chemistry for the design of large numbers of fluorescent chemical and 
biological probes. In recent years instead of using single organic dye probes, these organic 
fluorophores were encapsulated in a particle matrix. These particles are much brighter 
than the dyes alone because one particle contains several dyes molecules. In addition, 
these dyes are more photostable because the entrapment enhances the stability and 
biocompatibility of the fluorophores. The small size of the nanoparticles allows a high 
signal-to-noise ratio response and signal amplification, therefore improving the analytical 
sensitivity and the response time. More importantly, their molecular size minimizes 
physical perturbation of living cells. Generally, fluorescent nanoparticles show superior 
optical properties, which facilitate their application for single molecule imaging and long-
term tracking of biological molecules in vivo.96 
The need to trace the delivery of the nanoassemblies and to demonstrate the 
internalization of the drugs prompted us to prepare fluorescent hetero-nanoassemblies 
by mixing a paclitaxel–squalene conjugate (PTX-Sq) and a fluorescein–squalene conjugate 
(FITC-Sq) (Figure 6).97  
 
 
Figure 6. Structures of the paclitaxel- and fluorescein-squalene conjugates. 
 
Squalene-based Nanoparticles
 
 
34 
 
Paclitaxel 
 
Paclitaxel (PTX), a tetracyclic diterpenoid, was first isolated in 1971 from the Western Yew 
Taxus Brevifolia by Wani, Wall and co-workers, who established its structure by X-ray 
crystallographic methods98 (Figure 7). 
 
 
         
 
Figure 7. Paclitaxel (PTX) and Taxus Brevifolia. 
 
Different from most anticancer drugs, PTX acts as a microtubule-stabilizing drug, which 
inhibits cellular growth by preventing cytoskeletal microtubule depolymerisation to free 
tubulin and disrupting the balance between polymerization and depolymerisation, and 
thus leads to cessation of the cell cycle with arrest at the G2/M phase.99 
Despite its promising cytotoxic activity, many limitations in its clinical use are related to 
its low water solubility. For this reason, paclitaxel is usually formulated in adjuvant 
Cremophor EL, that anyway has been reported to cause serious side effects, including 
hypersensitivity reactions, nephrotoxicity, cardiotoxicity and neurotoxicity.100 
Furthermore, significant side effects are also induced due to paclitaxel nonspecific, 
indiscriminate biodistribution in the body after administration.  
Therefore, many kinds of PTX analogues have been prepared,101 on the base of SAR 
studies, in order to improve water solubility while maintaining the activity. 
Different approaches, obtained from SAR studies, for the preparation of paclitaxel 
analogues can be summarized as in Figure 8:102,103 
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Figure 8. SAR studies for paclitaxel. 
   
Another strategy is to find a different formulation to avoid the use of Cremophor EL, and 
also in this direction many efforts have been made and some good results have been 
obtained, such as those related to albumin-bound paclitaxel (Abraxane®).104,105,106 
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Synthesis of the conjugates  
 
To obtain the conjugate 2 (FITC-Sq), the first step was the preparation of the 1,1’,2-tris-
norsqualene alcohol 7. In particular, it was obtained starting from squalene (1), as 
described in Scheme 2. The crucial reaction is the formation of monobromohydrine 4 that 
was converted into 2,3-epoxide 5 by simple treatment with K2CO3. The oxidative cleavage 
of the epoxide furnished 1,1’,2-tris-norsqualene aldehyde 6107 and the subsequent NaBH4 
reduction secured the alcohol 7. 
 
 
Scheme 2. Synthetic pathway for the preparation of 1,1’,2-tris-norsqualene alcohol. 
  
The reaction of 1,1’,2-tris-norsqualene alcohol 7 with fluorescein isothiocyanate (FITC) in 
the presence of sodium hydride gave the stable compound 2 (Scheme 3).  
 
 
Scheme 3. Synthesis of the conjugate FITC-Sq (2). 
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As paclitaxel conjugate, we planned to use the recently described squalenoyl–paclitaxel 1 
that was recognized as being able to act as a prodrug and to self-assemble.83 PTX-Sq (1) 
was prepared following a procedure described by Dosio and co-workers. Compound 6 
was oxidized to the corresponding carboxylic acid 8 by treatment with H2SO4/Na2Cr2O7 
and then condensed to paclitaxel using EDC.HCl/DMAP as activating system (Scheme 4).  
 
 
Scheme 4. Synthesis of the conjugate PTX-Sq (1). 
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Nanoparticles preparation 
 
To verify the ability of compound 2 (FITC-Sq) to form nanoassemblies and of compounds 
1 and 2 to form hetero-nanoparticles (Figure 9), five different nanosuspensions were 
prepared by the solvent displacement method (Figure 10Figure 10).108  
 
 
Figure 9. Schematic representation of hetero-nanoparticles formation. 
 
A) FITC-Sq (2 mg/mL);  
B) PTX-Sq (2 mg/mL): FITC-Sq = 10 : 1;  
C) PTX-Sq (2 mg/mL): FITC-Sq = 20 : 1;  
D) PTX-Sq (2 mg/mL): FITC-Sq = 30 : 1;  
E) PTX-Sq (2 mg/mL).  
 
In the case of suspensions B, C and D, the final concentration (2 mg/mL) is referred to 
PTX-Sq, while the amount of FITC-Sq was calculated considering the molar ratios PTX-Sq: 
FITC-Sq (10:1, 20:1, 30:1).  
 
 
 
   
 
Figure 10. Schematic representation of the five mixtures. 
  
H
2
O (HPLC grade) 
PTX-Sq in MeOH (HPLC grade) 
FITC-Sq in MeOH (HPLC 
grade) 
A B C D E 
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Nanoparticles characterization 
 
Measurement of the mean diameter and polydispersity index by using dynamic light 
scattering (DLS) confirmed the presence of self-assemblies (Table 2). It was evident that 
by decreasing the amount of fluorescein–squalene conjugate 2, the mean diameter 
increased toward the value of the pure paclitaxel–squalene conjugate 1.  
Unfortunately, we were not able to obtain a precise measure for Z potential of most of 
the suspensions, but values very different one from the other (all the measurements 
were always repeated thrice). This could be due to intrinsic factors of our nanoparticles or 
to a malfunctioning of the instrument we used.  
 
  
Compound  
Mean Diameter 
(nm) 
Polydispersity 
Index 
Z potential 
(mV) 
A  FITC-Sq  196.4 0.232 -19.91 
B  PTX-Sq: FITC-Sq  10:1  149.4 0.147 n.d. 
C  PTX-Sq: FITC-Sq  20:1  171.9 0.179 n.d. 
D  PTX-Sq: FITC-Sq  30:1  225.4 0.190 n.d. 
E  PTX-Sq  231.6 0.270 n.d. 
 
Table 2. Mean diameter, polydispersity index and Z potential of the five mixtures. 
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Fluorescence emission 
 
To verify the relevance of the amount of fluorescein derivative and the pertinence of the 
nature of the samples (solutions or nanosuspensions), we measured the fluorescence 
emission of different mixtures deriving from nanoparticles or from simple dissolution, 
using a spectrofluorometer FP-750 (Jasco).  
For a better measurement nanoparticle samples were diluted with water (HPLC grade) 
and pure FITC-Sq was dissolved in MeOH (HPLC grade) in order to have the main 
component of the mixture at a fixed concentration. The results we obtained are 
summarized in the following graphs.  
 
 Graph A: FITC-Sq at different concentrations (samples as nanoparticles). Samples 
with higher amounts of FITC-Sq possess a higher fluorescence emission. 
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 Graph B: PTX-Sq at a fixed concentration (20 μM) with different amounts of FITC-
Sq compared to FITC-Sq 20 μM (samples as nanoparticles). Also in this case, 
samples with higher amounts of FITC-Sq possess a higher fluorescence emission. 
 
 
 
 Graphs C, D and E: samples with different amounts of FITC-Sq (as nanoparticles) 
were compared to samples containing the same amounts of FITC-Sq but in 
solution. Noteworthy, the samples of nanosuspensions displayed a higher 
emission of fluorescence than the corresponding solutions and, at each value of 
FITC-Sq concentration, the mixture of PTX-Sq and FITC-Sq displayed a higher 
emission than FITC-Sq alone. 
This can be explained by the fact that the more hydrophobic the environment is, 
the higher the emission: thus, a nanosuspension results to be a more 
hydrophobic environment than a methanolic solution even if the sample is 
diluted with water. Moreover, the presence of PTX-Sq in a 10:1 ratio respect to 
FITC-Sq further increase the hydrophobicity of the system. 
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Graph C: Fixed FITC-Sq concentration: 2 μM 
 
 
 
 
 
Graph D: Fixed FITC-Sq concentration: 1 μM 
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Graph E: Fixed FITC-Sq concentration: 0.67 μM 
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In vitro evaluation: cell internalization 
 
To verify the capability of nanoassemblies to enter the cell, A549 cells were incubated 
with suspensions of hetero-nanoparticles 1/2 at two different molar ratios (10:1 and 
30:1). Figure 11Figure 11 shows that after different incubation times (10, 30, and 60 min), 
fluorescent entities accumulate in the perinuclear region.  
Figure 11. Right columns show actin filaments (red) and nuclei (blue), whereas white lines in the left columns 
mark the cell boundaries. Top row (Control) shows A549 cell that were not incubated with PTX-Sq/FITC-Sq co-
nanoassemblies. Scale bar = 20 µm. 
 
We also took advantage of live cell imaging to directly visualize moving nanoparticles and, 
as reported in Figure 12, it is possible to recognize cells that contain fluorescent spherical 
spots whose perceptible diameter (< 450 nm) is consistent with that of the reported 
mean diameter (see Table 2). Thereby showing that the fluorescence inside the cells is 
really due to the nanoassemblies and not to diffused compound 2.  
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Figure 12. Frames from a time-lapse series of A549 cells exposed to nanoassemblies 1/2. The incubation time 
is shown on each frame; white lines mark the cell boundaries and the arrowheads indicate the initial position 
of the fluorescent particle. Image on the top left shows the phase contrast channel. Scale bar = 5 mm.  
 
In vitro evaluation: cytotoxic activity 
 
After proving that nanoassemblies 1/2 are able to cross the cell membrane, we wondered 
if the contained paclitaxel retains its antitubulin effect. Microscopy analyses (Figure 13) 
reveal that control cells are spread with a well-organized microtubule network, whereas 
cells treated with either paclitaxel or nanoassemblies of 1/2 become smaller and 
roundish, as if to signify they were dying and detaching from the plate.  
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Figure 13. A549 cells were treated for 10, 30, and 60 min with paclitaxel (PTX) or nanoassemblies 1/2. Left 
column shows the a tubulin staining, whereas the right column shows both a tubulin (red) and fluorescent 
compound (green). Top row displays untreated cells (CONTROL). Scale bar = 20 mm.  
 
Furthermore, both microtubule bundles and tubulin accumulation are noticeable, 
meaning that the observed changes in cell shape are a result of aberrant organization of 
the microtubule cytoskeleton. To further certain that paclitaxel in the nanoassemblies 
target microtubules, we removed the unassembled pool of tubulin, as previously 
described.109 As highlighted by the arrowheads, paclitaxel decorates microtubule bundles 
(Figure 14).  
 
 
 
 
 
 
 
1/2 PTX 
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Figure 14. Untreated A549 cells (CONTROL) or A549 treated 60 minutes with nanoassemblies 1/2 were 
extracted and immune-stained for α tubulin (α TUB, blue) and paclitaxel (PTX, red); fluorescent compound is 
shown in green. Arrowheads indicate a microtubule bundle. Scale bar = 20 μm.  
  
Therefore, we conclude that nanoassemblies 1/2 cross the cell membrane and act on the 
microtubule cytoskeleton by inducing typical taxol-like effects.  
We suppose that the internalization of nanoassemblies 1/2 has occurred even though the 
alternative possible pathway envisages efflux through the cellular membrane of the 
partially disassembled compounds after the approach of the nanoparticles to the cell. 
This second possibility does not affect the relevance of creating self-assembled hetero-
nanoparticles.  
The self-assembly ability of lipid–drug conjugates is advantageous for the preparation of 
fluorescent hetero-nanoparticles that can help follow the dynamic of the delivery. The 
easy formation of nanoparticles by simple mixing of the lipid–drug conjugates makes this 
strategy simple to apply for different types of drugs and biological targets.  
  
1
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2.3 Cyclopamine-Paclitaxel hetero-nanoparticles 
 
Tumors are heterogeneous, composed of distinct types of cells including cancer stem cells 
(CSCs), which exhibit high clonogenic capacity and the ability to reform parental tumors 
upon transplantation. Existing anticancer therapies are in most cases palliative rather 
than curative, not being able to prevent re- lapse. One possible explanation is that current 
treatments target the more differentiated tumor cells resulting in tumor regression; they 
do not target CSCs, and subsequently there is a relapse of the disease. Indeed, resistance 
to therapy has been shown for several types of CSCs. Therefore, a combination of agents 
against both CSCs and bulk tumor cells may offer improved therapeutic benefits.110 In this 
field, the use of a combination of paclitaxel, a known microtubule stabilizer, and 
cyclopamine, a natural alkaloid acting as Hedgehog signalling pathway (Hh) inhibitor, has 
been reported for the treatment of some prostate cancer cells resulting in decreased 
proliferation and increased apoptosis.111,112  
 
Stem cells and cancer 
 
Normal adult multipotent stem cells are usually able to self-renew, producing at least one 
progeny cell with a similar developmental capacity and many evidences indicate that this 
cell population, through initial genetic or epigenetic alterations, can become responsible 
for the development of several tumors through a progressive establishment of a CSC 
population. 
The CSCs model suggests that tumor progression, metastasis and recurrence after 
therapy can be driven by a rare subset of tumor cells that have the capacity to self-renew, 
while the bulk of the tumor does not have this capacity. 
For these reasons, the deregulation of the self-renewal process may be a key event in 
carcinogenesis, and while self-renewal can drive tumorigenesis, the differentiation 
process may contribute to tumor phenotypic heterogeneity. 
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CSCs as targets in cancer treatment 
 
It is well known that several cancers are peculiarly resistant to conventional radio- and 
chemotherapy that typically kill the majority of cancer cells. This clinical response may 
reflect the targeting of the bulk of non-stem cell population. 
On the other hand, there are several specific key intracellular signaling pathways 
implicated in CSCs self-renewal and proliferation processes that appear to be promising 
therapeutic targets. 
An ideal therapeutic strategy might be to sensitize CSCs to chemo- and radiotherapy by 
inhibiting their stem properties and then by promoting a direct cytotoxicity. Since the 
CSCs population is driven by embryonic signaling pathways, the targeting of these 
pathways could result in a better outcome of the therapy: in this direction, many drugs 
for the inhibition of embryonic signaling pathways are currently under development. 
 
 
Hedgehog Signalling Pathway: a new biological target for the design of new 
anticancer compounds 
 
Some of the most characterized signalling pathways controlling self-renewal and 
differentiation in adult stem cells, such as Wnt/b-catenin, Hedgehog, Notch and TGF-
b/BMP pathways, are frequently modulated in cancer by epigenetic mechanisms. 
Hedgehog (Hh) is a key signaling pathway for the regulation of embryonic development 
and tissue repair, mainly through the control of stem and progenitor cells (e.g. neural 
stem cells) and for the control of a number of genes involved in cell fate determination 
and stemness features. When hyperactivated by genetic and/or epigenetic alterations, Hh 
pathway promotes tumorigenesis in several tissues by subverting the regulation of 
stemness-determining genes overexpressed in that type of cancer. 
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Normal Hh signalling 
 
Binding of Hh to its receptor Patched (Ptch-1) activates the transmembrane protein 
Smoothened (SMO), which subsequently activates the Gli family of transcription factors, 
leading to activation of target genes (Figure 15): 
 
 
 
Figure 15. Normal Hedgehog signalling pathway. 
 
Hedgehog signaling in cancer 
Aberrant Hh signaling occurs in some cases because of a ligand-independent activation of 
SMO due to a mutation in PTCH1 or in SMO (Figure 16), but it generally happens through 
ligand-dependent mechanisms. Increased Hh ligand expression leads to increased Hh 
signaling in the activated target cell. This can theoretically occur through either an 
autocrine mechanism  where the malignant cells both secrete and respond to Hh ligand, 
or through a paracrine mechanism  where the secreting cell and recipient target cell are 
different. Even if the autocrine mechanism has been reported for multiple tumor types, 
the currently overall favored mechanism is the paracrine model, based partly on evidence 
that tumor cells do not appear to respond to Hh ligand themselves.113  
One proposed explanation has been that tumor cells lack the primary cilium necessary for 
canonical Hh signaling through PTCH1 and SMO. 
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Figure 16. Hedgehog signalling pathway in cancer. 
Hedgehog inhibitors 
On the base of the acquired knowledge concerning the signaling steps of the Hh signaling 
pathway, it is possible to identify different potential ways to inhibit this pathway in 
cancer. To date, the best-characterized approach is to target the SMO receptor with small 
molecule inhibitors, and many of such inhibitors are under clinical trial investigation.  
Alternatively, preventing SMO from converting from the inactive to the active form 
should also achieve the same result.  
The limitation with these two approaches is that they will fail if activation occurs by 
alteration of the signaling pathway downstream of SMO. 
Drugs that can interfere with the Hh signaling pathway downstream of SMO are therefore 
also of potential therapeutic benefit. 
 
 
We decided to examine self-assembled hetero-nanoparticles that incorporate two 
different drugs: paclitaxel and cyclopamine (Figure 17).114 A ternary combination 
obtained by further addition of a tetramethylrhodamine–squalene conjugate generated 
fluorescent nanoparticles that could be used to observe the cellular internalization by 
confocal microscopy and super-resolution dSTORM (direct stochastic optical 
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reconstruction microscopy).115  
 
 
Figure 17. Structures of the drugs paclitaxel and cyclopamine and of the dye tetramethylrhodamine. 
 
Cyclopamine 
 
The Veratrum alkaloid known as cyclopamine (CYP) was the first agent that was found 
capable of disrupting the Hh signalling pathway. 
Cyclopamine belongs to the family of jervine alkaloids, which constitute the majority of 
Veratrum secondary metabolites. The association of Veratrum Californicum (Figure 18) to 
sheep congenital deformities during the 1950s raised 
the possibility that jervine alkaloids could be potent 
teratogens. Later studies confirmed that jervine and 
cyclopamine (Figure 19) given during gestation can 
directly induce cephalic defects in lambs, including 
cyclopia. 
Figure 18. Veratrum Californicum. 
 
Figure 19. Structure of jervine and cyclopamine. 
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Cyclopamine116 was shown to be a potent antagonist of the Hh pathway, directly acting 
on the protein Smo, and has been shown to have antitumor activity in several xenograft 
models.  
Despite the attractive pharmacological profile of cyclopamine, its use as a systemic 
treatment may be limited by its poor aqueous solubility (5g/ml) and stability in acid. In 
fact, cyclopamine readily converts to veratramine as a result of an acid-catalyzed opening 
of the spirotetrahydrofuran E ring followed by rapid aromatization of the D ring (Figure 
20). Veratramine, while not acting as Hh antagonist, has been shown to interact with 
several other receptors and cause hemolysis. 
 
Figure 20. Structure of cyclopamine and veratramine. 
 
In order to obtained more stable and soluble hedgehog inhibitors, many efforts have 
been made for the preparation of cyclopamine analogues.117,118  
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2.3.1 Cyclopamine nanoparticles 
  
Synthesis of the conjugates 
 
We first investigated the synthesis of cyclopamine–squalene conjugates incorporating a 
disulfide bond. In Scheme 5 we report a successful synthesis that relies on the protection 
of the amino group.119 Condensation of cyclopamine N-Fmoc120 with dicarboxylic acid 
monoesters 11 and 12, respectively synthetized by condensation of 1,1’,2-tris-
norsqualene alcohol 7 with 4,4′-dithiodibutyric acid or sebacic acid,  in the presence of 
EDC–DMAP and subsequent removal of the protecting group led to cyclopamine 
conjugates 13 and 14.  
 
Scheme 5. Synthesis of the cyclopamine-squalene conjugates. 
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Nanoparticles characterization 
 
The obtained conjugates were used to form nanoparticles by solvent-displacement 
method (Figure 21Figure 21) and were characterized by dynamic light scattering (DLS) 
(Table 3). 
 
 
Figure 21. Nanoparticles formation. 
 
Compound  Mean Diameter (nm) Z potential (mV) 
13 105±1 +37.8±3.3 
14 240±2 +38.4±4.3 
 
Table 3. Cyclopamine-nanoparticles characterization. 
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In vitro evaluation 
 
To assess the effect of the compounds 13 and 14 on cancer cell growth, we evaluated 
their biological effect in U251 glioblastoma cell line taking into account that their 
resistance is associated also with an increase of glutathione (GSH) level.121 We found 
compound 14 to be the more active (Figure 22).  
 
 
 
 
 
 
 
 
 
Figure 22. A) Effect on U251 glioblastoma cell line, at the indicated concentrations after 48h of culture;  B) 
Effect on the proliferation of U251 cells, at a concentration of 25 M after 48h culture; C) Quantitative RT-
PCR analysis of the mRNA expression of the main genes of Hh signalling pathway in U251 glioblastoma cells 
24h after the addition in culture of indicated compounds at a concentration of 25 M. 
 
Our results show that the compound 14 inhibited proliferation (Table 4) and induced 
apoptosis at comparable levels to that of cyclopamine, and this effect was indeed 
mediated by inhibition of the Hh pathway.  
  
Cyclopamine 
13 
14 
13 
14 13 
14 
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Compound IC50 (µM) 
 #83 #110 OVCAR5 U251 
CYP > 50 > 50 > 50 30 
13 n.a n.a. n.a. 68 
14 34 40 42 40 
Table 4. IC50 values determined with different cell lines. 
 
In our proposal, compound 13 releases the drug as a consequence of the cleavage of the 
disulfide bond by GSH, which is particularly present inside the cancer cells. If the release 
of cyclopamine is responsible for the activity, the unexpected result seems to suggest a 
better release in compound 14. With the aim to evaluate the chemical reactivity induced 
by the presence or the absence of the disulfide bond, we studied the behaviour of both 
compounds 13 and 14 in the presence of GSH. With ESI mass spectrometry, we had the 
possibility of detecting the release of cyclopamine from both of the compounds. In the 
absence of GSH we observed only the peaks of the conjugate.  
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2.3.2 Cyclopamine-Paclitaxel hetero-nanoparticles 
 
Given the better activity of compound 14, we decided to use compound 14 and 
compound 15 (previously described by our research group)95 to form hetero-
nanoparticles (Figure 23). Hetero-nanoparticles having different molar ratios of the two 
compounds were prepared; the best results were obtained with the most active 
nanosuspension (molar ratio 14/15 23 :1).  
 
Figure 23. Structures of conjugates 14 and 15. 
 
Nanoparticles Characterization 
 
Hetero-nanoparticles were prepared by solvent-displacement method and they were 
characterized using DLS (Table 5) and the morphology was evaluated by AFM (Figure 24). 
  
Compound  Mean Diameter (nm) Z potential (mV) 
14 240±2 +38.4±4.3 
15 437±5 -35.7±0.1 
14/15 229±2 +26.4±1.7 
Table 5. Diameter and Z potential of the obtained nanoparticles. 
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Figure 24. AFM picture showing the morphology of 14/15 hetero-nanoparticles (molar ratio 23:1). 
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In vitro evaluation 
 
Biological evaluation of hetero-nanoparticles (Table 6) showed that the activity of the two 
drugs was maintained and comparable to the activity of nanoassemblies of compounds 
14 and 15 in different cellular systems, that is, OVCAR5 (ovarian cancer cell) and #83 and 
#110 (ovarian tumor-initiating cells).122  
Compound IC50 (µM) 
 #83 #110 OVCAR5 U251 
CYP > 50 > 50 > 50 30 
14 34 40 42 40 
15 < 3 < 3 < 3 4 
14/15 16 15 32 28 
Table 6. IC50 values determined with different cell lines. 
 
The induction of apoptosis (Figure 25) showed a combined effect. It is worth noting that 
the IC50 value reported for 14/15 NPs refers to sum of the concentrations of the two 
compounds assembled in the hetero-nanoparticles: this means that for the reported 
values 23/24 is due to compound 14 and 1/24 to compound 15. As an example, the IC
50 
obtained for 14/15 in U251 cells corresponds to a concentration of compound 15 equal to 
1.2 mm and to a concentration of compound 14 equal to 26.8 mm, both lower than the 
IC
50 obtained for the corresponding homo-nanoparticles.  
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Figure 25. Apoptosis of the U251 glioblastoma cell line, 24h upon addition of the mentioned compounds; CYP 
(Cyclopamine): 2.07 µM; PTX (Paclitaxel): 0.094 µM; 14: 2.07 µM; 15: 0.094 µM; 14/15 (NP): 2.07 µM / 0.094 
µM. 
 
  
Control CYP PTX 14 15 14/15 
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2.3.3 Cyclopamine-Paclitaxel-Tetramethylrhodamine 
hetero-nanoparticles 
 
Next, we aimed to monitor the ability of the hetero-nanoparticles to pass through the cell 
membrane in biological media. In order to apply fluorescence microscopy, we assembled 
hetero-NPs that incorporated a squalene–tetramethylrhodamine (TAMRA) conjugate 
(16). TAMRA was chosen as a fluorescent dye because it is used in super-resolution 
localization microscopy techniques such as dSTORM (direct stochastic optical 
reconstruction microscopy).123 
Synthesis of the conjugate 
 
The fluorescent squalene conjugate was synthesized by reaction of 
tetramethylrhodamine isothiocyanate with compound 7 in the presence of sodium 
hydride (Scheme 6).  
 
Scheme 6. Synthesis of the fluorescent squalene conjugate TAMRA-Sq. 
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Nanoparticles characterization 
 
The fluorescent hetero-nanoparticles were obtained by the solvent-displacement method 
by mixing compounds 14, 15 and 16 in a 23:1:15 molar ratio; we confirmed by DLS the 
formation of the nanoparticles (mean diameter: 224±2 nm, zeta potential: + 43.5±3.4 
mV).  
In vitro evaluation 
 
Breast cancer MCF-7 cells were treated with the fluorescent hetero-nanoparticles for 20 
min and imaged by multiple fluorescence microscopy methods. Three-dimensional 
confocal microscopy (Figure 26) allowed the identification of the fluorescent 
nanoparticles in the cytoplasm of the cells, providing evidence that the nanoparticles are 
capable of permeating the cellular membrane.  
                       
 
Figure 26. Cellular imaging of three-component 14/15/16 hetero-NPs. Confocal imaging of cells treated for 20 
min with fluorescent hetero-nanoparticles. Displayed are the orthogonal projection of the three-dimensional 
stack for two MCF-7 cells. The bottom cell shows a bright fluorescent dot (a putative hetero-NP) in the 
cytoplasmplasm close to the nucleus. 
However, to provide an estimation of the size of the nanoparticles, the resolution of 
conventional microscopy is not sufficient. We therefore applied super-resolution 
microscopy (dSTORM)124 to quantify the diameter of the bright particles detected inside 
the cells. Figure 27 shows images of the cells recorded after 1.5 h of incubation. The 
enlarged detail of the nanoparticle served to quantify its diameter: 156 nm. The diameter 
is in good agreement with our previous measurements by DLS (224±2 nm).  
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Figure 27. Cellular imaging of three-component hetero-NPs. Results obtained from application of super-
resolution dSTORM: shown are the conventional widefield image (top left) and the super-resolution image 
(bottom left) of the same cell together with a enlarged detail of the NP (bottom right) and the quantification 
of the diameter of the shown NP in the conventional and the super-resolution image (top right). FWHM = full 
width at half maximum. 
 
In order to monitor the behaviour of the internalized nanoparticles, we performed 
dStorm imaging at different incubation times. In this way we confirmed (Table 7) a 
progressive increase in the variability of the nanoparticle diameter—as indicated by the 
increase in the coefficient of variation—which might be an indication of their tendency to 
disassemble.  
Time after 
incubation (h)  
Mean Diameter (nm) 
Coefficient of 
variation 
Number of cells 
0.5 147±17 0.12 10 
1 140±31 0.22 10 
1.5 178±63 0.36 12 
 
Table 7. Mean diameter of three-component hetero-NPs (14/15/16 = 23:1:15) at different times after the 
incubation. 
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We have demonstrated the possibility of forming hetero-nanoparticles containing two 
different drugs and we also established that the two drugs that do not influence each 
other’s activity. We confirmed the possibility of following the internalization mechanism 
by the addition of a third dye-based compound using super-resolution microscopy.  
The functionalization of different known drugs with a cleavable linker and a proper 
lipophilic chain that induces self-assembly and the generation of hetero-nanoparticles 
could be exploited for personalized treatment of different types of diseases, and it may 
be possible to trace these nanoparticles in the cells by imaging.  
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2.4 Cyclopamine-Doxorubicin hetero-nanoparticles 
 
Pursuing our interest in self-assembled nanoparticles, we investigated he combination of 
cyclopamine (CYP) and doxorubicin (DOXO) conjugates (Figure 28) with the aim to 
demonstrate the formation of hetero-NPs that could improve the performance given by 
the use of the simple parental drugs.125  
 
Figure 28. Structure of the CYP and DOXO conjugates. 
 
Specifically, we decided to investigate the combination of cyclopamine-squalene (CYP-Sq) 
derivative 14, active on different types of cancer cells as previously cited, with 
doxorubicin-squalene (DOXO-Sq) 17, described as able to improve the anticancer efficacy 
and the therapeutic index of DOXO.126  
Doxorubicin 
Doxorubicin (DOXO), isolated from the bacterium Streptomyces peucetius var. caesius, is 
an anthracycline antibiotic and it is the 14-hydroxylated congener of daunorubicin (Figure 
29).  
 
Figure 29. Structures of doxorubicin and daunorubicin. 
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Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA 
replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits 
topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA 
linked complex during DNA replication and subsequently prevents the ligation of the 
nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free 
radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; 
the formation of oxygen free radicals also contributes to the toxicity of the anthracycline 
antibiotics, namely the cardiac and cutaneous vascular effects.  
Doxorubicin is one of the leading anticancer drugs in clinical oncology with a broad 
spectrum of activity against various solid and hematologic neoplastic diseases. The 
effectiveness of doxorubicin is impeded by acute and subacute side effects, mainly dose-
limiting irreversible cardiotoxicity and myelosuppression.127 In an attempt to reduce the 
side-effects of doxorubicin and to improve its anticancer efficacy, various nanocarriers of 
doxorubicin and daunorubicin have been developed, including micelles, dendrimers, 
solid-lipid, and polymer nanoparticles.128,129,130,131,132 
 
Nanoparticles characterization 
 
Hetero-NPs were obtained by mixing two squalene conjugates, CYP-Sq (14) and DOXO-Sq 
(17), prepared according to the previously described approaches126. All NPs were 
prepared by solvent-displacement method, using THF as organic solvent and without 
adding any surfactant. 
Five different nanosuspensions were prepared: 
 NP0: CYP-SQ (10 µM) 
 NP1: CYP-SQ/DOXO-SQ 1:1 (10 µM, 10 µM) 
 NP2: CYP-SQ/DOXO-SQ 5:1 (10 µM, 2 µM) 
 NP3: CYP-SQ/DOXO-SQ 10:1 (10 µM, 1 µM) 
 NP4: DOXO-SQ (10 µM) 
14 and 17 were co-nanoprecipitated at 1:1, 5:1, 10:1 molar ratios (Table 8, NP1, NP2 and 
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NP3 respectively) with a constant concentration of 14, giving a suspension of narrow 
monodispersed NPs. 14 and 17 were also separately nanoprecipitated to obtain NPs of 
CYP-Sq or DOXO-Sq alone (Table 8, NP0 and NP4).  
All the formulations were characterized in terms of mean diameter and zeta potential of 
the NPs. As showed in Table 8, CYP-Sq and DOXO-Sq alone spontaneously self- assembled 
in water forming NPs; however, DOXO-Sq NPs   displayed a larger mean diameter of 
about 400 nm.  When  DOXO-Sq was formulated with an equimolar amount of  CYP-Sq 
(NP1), the mean size drastically reduced from 400 to about 130 nm; in these conditions 
DOXO-SQ probably took a different supramolecular organization and mutual interactions 
 between the two squalene conjugates caused the formation of  smaller nanoparticles. 
The addition of DOXO-Sq in various molar ratios did not influence the mean size of CYP-
SQ NPs. The zeta potential of all NPs is highly positive; for NPs containing DOXO-Sq it is 
higher than the one of CYP-Sq-containing NPs. After 4-weeks storage at 4°C in water, no 
appreciable NPs size and/or zeta potential changes were detected by DLS for all 
formulations and no NPs aggregation was observed.  After dilution with fetal bovine 
serum, NP1 did not show aggregation, even after 24 h at 4°C. On the contrary, the 
incubation in PBS 10 mM resulted in an increase of the NP1 mean  diameter up to about 
400 nm (700 nm after 24 h). 
 
 
Mean Diameter (nm) Polydispersity index Z potential (mV) 
NP0 127.8±0.723 0.106 +44.1±2.048 
NP1 126.9±1.108 0.102 +61.6±4.18 
NP2 129.4±1.589 0.109 +50.9±0.404 
NP3 127.7±0.734 0.106 +56.8±2.66 
NP4 395.4±6.739 0.122 +58.1±0.643 
Table 8. Nanoparticles characterization. 
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In vitro evaluation 
 
With the aim to confirm the maintenance of the biological activity of the parental drugs, 
and in particular of DOXO, the obtained NPs and the relative single conjugates 14 and 17 
were evaluated on 4 ovarian cancer cell lines (A2780, IGROV, OVCAR432 and OVCAR433) 
with similar results. Figure 30 reports the results obtained in IGROV cells. As illustrated in 
Figure 30, NP1 was the most active NP formulation with a cytotoxic activity similar to 
CYP:DOXO (1:1) and to DOXO (10µM). In all these cell lines CYP was not very active, likely 
to the fact that these cells do not have an activated Hedgehog pathway. 
 
 
 
Figure 30. Cytotoxic activity of the different NP formulation and single or combined treatment agents in 
IGROV ovarian cancer cell line. Concentration of the samples: NP1: [CYP-SQ]=[DOXO-SQ]= 10 µM; NP2: [CYP-
SQ ]=10 µM, [DOXO-SQ]=2 µM; NP3: [CYP-SQ ]=10 µM, [DOXO-SQ]=1 µM; 14:17 (1:1): [CYP-SQ]=[DOXO-
SQ]=10 µM; 14:17(5:1): [CYP-SQ]=10 µM, [DOXO-SQ]=2 µM; 14:17(10:1): [CYP-SQ]=10 µM, [DOXO-SQ]=1 µM; 
CYP:DOXO (1:1): [CYP]=[DOXO]=10 µM, CYP:DOXO (5:1): [CYP]=10 µM, [DOXO]=2 µM, CYP:DOXO (10:1): 
[CYP]=10 µM, [DOXO]=1 µM. 
In vitro evaluation: cell internalization 
 
As the best cytotoxic activity was observed with NP1 formulation, we next verified the 
dynamic of its internalization into ovarian cancer cells. To this aim, we applied confocal 
microscopy on cultured IGROV cells at different time points (i.e. 1.5, 4 and 24 h) following 
incubation with hetero-nanoparticles NP1 (Figure 31). Longer incubation with the NPs 
resulted in the increase of the intracellular fluorescence in the 560-660 nm band, 
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corresponding to the emission of DOXO. Interestingly at the latest point (24 h), DOXO is 
observed in the cell nucleus, suggesting that the active compound can be released from 
the hetero-NPs to reach the nuclear compartment. 
 
Figure 31. Confocal microscopy on cultured IGROV cells at different times (i.e. 1.5, 4 and 24 h) following 
incubation with hetero-nanoparticles NP1. 
 
In vitro evaluation: cellular system with an activated Hedgehog pathway 
 
We next investigated in details the effect of the NPs in a cellular system with an activated 
Hedgehog pathway. Specifically, we used the human epidermoid carcinoma cell line 
A431, which carries a single point mutation in exon 23 of both alleles of Patched1 gene, 
resulting in a proline to leucine substitution and subsequent constitutive activation of the 
Hedgehog pathway.133 In a similar experimental setting, we studied the inhibition of 
proliferation and the apoptosis induction upon addition of CYP, DOXO and distinct ratios 
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of CYP:DOXO, conjugate 14, conjugate 17 and distinct ratios of 14 and 17, free or 
assembled in NPs.  
DOXO alone at 10 μM (Figure 32 A) was able to inhibit proliferation of more than 50%, 
and the addition of CYP further enhanced the cytostatic effect. The combination of 14 
and 17 in 1:1 molar ratio also resulted in inhibition of proliferation, although to a lesser 
extent. Interestingly, when NP1 was used, cell proliferation is essentially entirely blocked. 
The same trend appears when investigating cell death, with CYP and derivative 14 not 
causing significant apoptosis, DOXO and derivative 17, alone or in combination with CYP 
or derivative 14 inducing  apoptosis in 30-60% of the cells, while when assembled in NP1, 
practically all cells are dead (Figure 32 B). Notably, while  apoptosis is only observed at 
the 1:1 ratio of CYP:DOXO or of derivatives 14 and 17, inhibition of proliferation could be 
observed also at the ratio 5:1, potentially indicating that either lower concentration of 
DOXO or derivative 17 is necessary for the cytostatic function, or that apoptosis is a later 
stage event in this system.  
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Figure 32. Effect on proliferation (A) and viability (B) in the A431 cancer cell line of cyclopamine, doxorubicin 
(reported as Parental drugs), compounds 1 and 2 not nanoprecipitated (reported as Conjugates) and 
nanoprecipitated compounds 1 and 2 (reported as NP). Concentration of the samples: NP1 (nanoprecipitated 
CYP-Sq = DOXO-Sq = 10 μM); NP2 (nanoprecipitated CYP-Sq = 10 μM, DOXO-Sq = 2 μM; NP3 (nanopre- 
cipitated CYP-Sq = 10 μM, DOXO-Sq = 1 μM; 14:17 (1:1): CYP-Sq = DOXO-Sq = 10 μM; 14:17 (5:1): CYP-Sq = 10 
μM, DOXO-Sq = 2 μM; 14:17 (10:1): CYP-Sq = 10 μM, DOXO-Sq = 1 μM; CYP:DOXO (1:1): CYP = DOXO = 10 μM, 
CYP:DOXO (5:1): CYP = 10 μM, DOXO = 2 μM, CYP:DOXO (10:1): CYP = 10 μM, DOXO = 1 μM. Statistical sig- 
nificance (Student’s t test) compared to Control: ns, p>0.01; *, p < 0.01; **, p<0.001; ***, p<0.0001.  
 
Given the strong cytostatic and cytotoxic effect of the 10 μM equimolar concentration of 
CYP:DOXO and 14 and 17, free or assembled in NP1, we sought to investigate the dose 
response  of A431 cells to these formulations, so as to define the lowest  concentration 
required for a toxic effect. As shown in Figure 33, NP1 has a significant cytotoxic and 
cytostatic effect already at 2.5 μM, while the free drugs require at least 3-fold higher 
concentration to induce apoptosis. Small differences in the percentage of proliferating 
cells treated with 10 μM of compounds in the sets of experiments presented in the Figure 
32 A and Figure 33 A are a result of difference in confluence, since the first set of 
experiments was performed in 6-well plates and the latter in 24-well plates. Our results 
NPs Conjugates Parental drugs 
NPs Conjugates Parental drugs 
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show that the  combination of the compounds 14 and 17 assembled in NP1 exhibit 
strong cytotoxic and cytostatic effect on cells requiring  Hedgehog signalling even at low 
concentrations.   
 
 
 
 
 
 
 
 
Figure 33. Dose response of equimolar concentrations of CYP and DOXO as parental drugs (CYP:DOXO), 
conjugates (14:17) or assembled in nanoparticles (NP1). The effect on proliferation (A) and their cytotoxic 
potential (B) is estimated by FACS analysis of BrdU incorporation and cleaved PARP immunostaining 
respectively. Concentration of the samples: NP1: [CYP-SQ]=[DOXO-SQ]= 10 µM; 14:17(1:1): [CYP-SQ]=[DOXO-
SQ]=10 µM; CYP:DOXO (1:1): [CYP]=[DOXO]=10 µM. 
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In vivo evaluation 
Given the very promising results obtained by the in vitro experiments using cell lines, we 
sought to investigate whether these results could also be observed in vivo, now 
investigating both the antitumor activity and the toxicity of the formulation. We used a 
xenograft model, injecting A431 cells into the flank of immunosuppressed mice. When 
tumours reached 3 mm in diameter, mice were administered intraperitoneally twice 
weekly equimolar concentrations (4 mg/kg of derivative 14 and 5mg/kg of derivative 17) 
of 14, 17 and 14 /17 free or assembled in NP1, or solely the vehicle. Strikingly, when the 
derivative 17 is injected as a free drug, alone or together with 14, it induces very high 
toxicity and the mice die or have to be sacrificed due to weight loss and general health 
deterioration less than a week after treatment initiation (Figure 34 A). The derivative 14 
alone is not toxic, but does not have an effect on tumour growth. Although, when the 
same concentration of 14/17 is administered as self- assembled NPs, there is no toxicity 
and there is a significant delay in tumour growth compared to the control mice (Figure 34 
B).  
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Figure 34. In vivo effect of equimolar concentration of CYP and DOXO conjugates, alone or in combination, or 
assembled in nanoparticles (NP1). (A) Kaplan Meier survival plot of mice upon treatment-administration, as 
indicated, twice weekly. Note that conjugate 17 alone or in combination with conjugate 14 exhibits high 
toxicity. (B) Representative immunofluorescence images of tumours from mice treated with NP1 or vehicle, 
stained for pH3 labelling cells undergoing mitosis. Note the inhibition of proliferation upon treatment with 
NP1. The antibodies are colour-coded. (C) Histogram illustrating the quantification of proliferating cells in 
mice treated with NP1 or vehicle, as illustrated in (B). Results are expressed as pH3+ cells per optical field. (D) 
Follow up of tumour size over time, upon treatment as described in (A). 20 random images per tumour form 3 
separate tumours were counted. (E) Representative mosaic immunofluorescent images of tumours from mice 
treated with NP1 or vehicle, stained with Keratin 14 indicating differentiated cancer cells and vimentin 
labelling tumour-associated fibroblasts and cells undergone epithelial-mesenchymal transition. Note the 
striking difference in the differentiation of the tumours. The antibodies are colour-coded. (F) Histogram 
illustrating the quantification of differentiated areas in tumours from mice treated with NP1 or vehicle, based 
on the expression of Keratin 14. 20 random images per tumour form 3 separate tumours were counted.  
Concentration of the samples: NP1: CYP-SQ = DOXO-SQ = 10 µM; 14:17(1:1): CYP-SQ = DOXO-SQ =10 µM; 14 = 
10 µM; 17 = 10 µM. Statistical significance (Student’s t test): ns, p>0.01; ***, p<0.0001. Scale bars: Panel B, 
100 μm; Panel E, 1000 μm. 
 
Microscopic analysis of tumours from control mice and mice treated with NP1, 3 weeks 
after treatment, showed that the latter exhibit very strong inhibition of proliferation 
(Figure 34 C, D) and a more differentiated phenotype (Figure 34 E, F). The latter could 
have important implications in moderating the metastatic potential, although longer 
experiments should be performed  to investigate this possibility. Therefore, our in vivo 
14:17 14 17 
14:17 14 17 
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experiments unambiguously show that self-assembled NPs reduce  tumour growth and 
toxicity of chemotherapy; this could enable the administration of higher doses, thus more 
effective  cancer treatment.  
The results obtained demonstrated that the approach of the  self-assembled hetero NPs 
is a promising way to treat different types of cancer cells and it makes possible to 
modulate the ratio of the combined drugs. Moreover, these results point out the possible 
application of this approach in the personalized therapy.  
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General 
 
Thin-layer chromatography (TLC) was performed on Merck precoated 60F254 plates. 
Reactions were monitored by TLC on silica gel, with detection by Uv light ( = 254 nm) or 
by charring with 1% permanganate solution. Flash chromatography was performed using 
Silica gel (240-400 Mesh, Merck). NMR spectra were recordered with Brucker 300 and 
400 MHz spectrometers. Chemical shifts are reported in parts per million () downfield 
from tetramethylsilane (TMS). EI mass spectra were recorded at an ionizing voltage of 6 
kEv on a VG 70-70 EQ. ESI mass spectra were recorded on FT-ICR APEXII. Specific rotations 
were measured with a P-1030-Jasco polarimeter with 10 cm optical path cells and 1 ml 
capacity (Na lamp,  = 589 nm). Microwave assisted reaction were performed with Emrys 
Creator single-mode (power range 0-400 W from magnetron at 2.45 GHz). 
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Synthesis of 4 
 
 
 
To a solution of squalene (3, 4.290 g, 0.010446 mol) in THF (30 mL) H2O (5 mLl) is added 
and then THF is dropwise added to obtain a clear solution. N-bromosuccinimide (2.231 g, 
0.012535 mol) is portionwise added and the reaction mixture is stirred at room 
temperature for 3h. The solvent is removed under reduced pressure, brine (100 mL) is 
added and extracted with AcOEt (5x20 mL). The organic layers are dried over Na2SO4 and 
the solvent is removed under reduced pressure. The crude is purified by flash 
chromatography (CH2Cl2:Hex 1:1) to obtain 4 as a pale-yellow oil (1.652 g, Yield: 31%). 
 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 5.10-5.25 (m, 5H); 4.01 (dd, J=11.3 Hz, J=1.9 Hz, 1H), 
2.32-2.35 (m, 1H), 1.95-2.17 (m, 18H); 1.77-1.88 (m, 1H), 1.70 (s, 3H), 1.63 (bs, 15H), 1.37 
(s, 3H), 1.36 (s, 3H).  
 
13C-NMR (CDCl3, 100 MHz): δ(ppm)= 135.11, 134.89, 132.97, 131.24, 126.03, 124.47, 
124.26, 72.44, 71.01, 39.73, 38.18, 32.17, 28.28, 26.68, 25.75, 17.68, 16.03, 15.85.  
 
APCI-MS: m/z 507.3 [M]+. 
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Synthesis of 5 
 
 
 
To a solution of 4 (1.652 g, 0.003258 mol) in MeOH (60 mL) K2CO3 (0.898 g, 0.006517 mol) 
is added and the reaction mixture is stirred at room temperature for 2 h, then 
concentrated under reduced pressure. H2O (120 mL) is added and extracted with AcOEt 
(4x30 mL). The organic layers are dried over Na2SO4 and the solvent is removed under 
reduced pressure to obtain 5 as a yellow oil (1.360 g, Yield: 98%) without any further 
purification. 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 5.06-5.17 (m, 5H), 2.69 (t, J=6.1 Hz, 1H), 1.95-2.19 (m, 
20H), 1.68 (s, 3H), 1.60 (s, 3H), 1.58 (bs, 12H), 1.28 (s, 3H), 1.24 (s, 3H).  
 
13C-NMR (CDCl3, 100 MHz): δ(ppm)= 135.06, 134.89, 133.96, 131.18, 124.93, 124.26, 
64.17, 58.27, 39.72, 36.31, 28.25, 27.46, 25.69, 24.89, 18.72, 17.67, 16.00.  
 
APCI-MS: m/z 427.3 [M+1]+. 
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Synthesis of 6 
 
 
 
To a solution of H5IO6 (1.379 g, 0.006058 mol) in H2O (5 mL) a solution of 5 (1.434 g, 
0.003366 mol) in dioxane (12 mL) is added and the reaction mixture is stirred at room 
temperature for 2h. H2O (150 mL) is added and extracted with AcOEt (3x40 mL). The 
organic layers are washed with brine (100 mL) and H2O (100 mL), then dried over Na2SO4 
and concentrated under reduced pressure to obtain 6 as a pale yellow oil (1.111 g, Yield: 
86%) without any further purification. 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 9.73 (s, 1H), 5.06-5.13 (m, 5H), 2.49 (t, J=7.1 Hz, 2H), 
2.30 (t, J=7.1 Hz, 2H), 1.97-2.10 (m, 16H), 1.67 (s, 3H), 1.55 (bs, 15H).  
 
13C-NMR (CDCl3, 75 MHz): δ(ppm)= 202.65, 135.11, 134.88, 134.77, 132.86, 131.23, 
125.41, 124.52, 124.37, 124.25, 67.06, 42.14, 39.73, 39.51, 31.83, 28.24, 26.73, 26.62, 
25.68, 17.66, 16.01.  
 
APCI-MS: m/z 385.3 [M+1]+. 
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Synthesis of 7 
 
 
 
To a solution of 6 (1.111 g, 0.002893 mol) in MeOH (45 mL) NaBH4 (0.055 g, 0.001446 
mol) is portionwise added and the reaction mixture is stirred at room temperature for 1 
h. HCl 1M is added to quench the unreacted NaBH4. The solvent is the removed under 
reduced pressure, H2O (150 mL) is added and extracted with AcOEt (3x40 mL). The 
organic layers are dried over Na2SO4 and concentrated under reduced pressure to obtain 
7 as a colorless oil (1.016 g, Yield: 91%) without any further purification. 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 5.08-5.13 (m, 5H), 3.61 (t, J=6.3 Hz, 2H), 1.99-2.08 (m, 
18H), 1.78-1.85 (m, 2H), 1.67 (s, 3H), 1.59 (s, 15H).  
 
13C-NMR (CDCl3, 75 MHz): δ(ppm)= 135.11, 134.92, 134.54, 131.24, 125.83, 124.42, 
124.26, 62.80, 39.72, 35.99, 30.73, 28.24, 26.60, 25.67, 17.66, 15.99.  
 
APCI-MS: m/z 387.3 [M+1]+. 
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Synthesis of 8 
 
 
 
Sodium dichromate dihydrate (6.350 g, 0.021780 mol) was slowly added at 0°C to a 
solution of sulfuric acid (11.600 mL, 0.217796 mol) in H2O (110 mL). The resulting solution 
was then added to a solution of 6 (7.940 g, 0.021778 mol) in Et2O (160 mL) and stirred at 
0 °C for 2 h. The reaction mixture was washed with brine (3 x 1000 mL) until neutral pH, 
then dried over Na2SO4 and evaporated under reduced pressure. The crude material was 
purified by flash chromatography (petroleum ether/Et2O 95:5) obtaining 8 as a colorless 
oil (2.862 g, Yield: 35%). 
 
1H-NMR (Acetone-d6, 300 MHz): δ (ppm) = 5.11 (m, 5H), 2.38 (t, J=7.1 Hz, 2H), 2.26 (t, 
J=7.1 Hz, 2H), 2.13-1.86 (m, 16H), 1.65-1.59 (m, 15H), 1.26 (s, 3H).  
 
EI-MS: m/z 400 [M]+. 
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Synthesis of 1 
 
 
To a solution of paclitaxel (1.200 g, 0.001405 mol) in CH2Cl2 (30 mL) EDC.HCl (0.270 g, 
0.001405 mol), DMAP (0.120 g, 0.000983 mol) and 8 (0.562 g, 0.001405 mol) were added 
and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture 
was then extracted with HCl 0.1 M (3 x 15 mL), the organic layers were dried over Na2SO4 
and evaporated under reduced pressure. The crude material was then purified by flash 
chromatography (CH2Cl2/AcOEt from 95:5 to 80:20) affording 1 as a white solid (1.128 g, 
Yield: 65%). 
 
1H NMR (CDCl3, 300 MHz): δ (ppm) = 8.13 (d, J = 7.3 Hz, 2H), 7.75 (d, J = 6.9 Hz, 2H), 7.62 
(t, J = 7.1 Hz, 1H), 7.53-7.49 (m, 3H), 7.43-7.35 (m, 7H), 6.91-6.85 (m,1H), 6.35 (s, 1H), 
6.24-6.19 (m, 1H), 5.99-5.88 (m, 1H), 5.69-5.65 (m, 1H), 5.53-5.48 (d, 1H), 5.20-5.16 (m, 
5H), 4.97-4.90 (m, 1H), 4.44-4.39 (m, 1H), 4.33-4.28 (m, 1H), 4.20-4.16 (m, 1H); 3.85-3.81 
(m, 1H), 2.55-2.48 (m, 1H), 2.49 (s, 3H), 2.45-2.38 (m, 2H), 2.30-2.27 (m, 2H), 2.23 (s, 3H), 
2.09 (s, 3H), 2.00-1.98 (m, 16H), 1.97-1.95 (m, 1H), 1.75-1.69 (m, 1H), 1.67 (s, 3H), 1.61-
1.55 (m, 18H), 1,28-1.23 (m, 1H), 1.21 (s, 3H), 1.13 (s, 3H).  
 
ESI-MS: m/z 1237.2 [M+H]+.  
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Synthesis of 2 
 
 
 
To a solution of 7 (0.040 g, 0.000103 mol) in dry DMF (2 mL) NaH (0.003 g, 0.000103 mol) 
was added and stirred at room temperature for 3 h. Then FITC (0.041 g, 0.000103 mol) 
was added and the reaction was stirred in the dark at room temperature for 72 h. Then 
the volatiles were removed under reduced pressure affording 2 without any further 
purification. 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 7.20-6.50 (m, 9H), 5.23-5.00 (m, 5H), 4.55 (bs, 1H), 
4.10 (t, J=7.1 Hz, 2H), 2.19-1.72 (m, 20H), 1.65 (s, 3H), 1.57 (bs, 15H).  
 
ESI-MS: m/z 775.7 [M-2]+. 
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Synthesis of 10 
 
 
 
To a solution of cyclopamine (0.045 g, 0.000109 mol) in dry CH2Cl2 (2 mL) Fmoc-OSu 
(0.044 g, 0.000131 mol) is added and the reaction mixture is stirred at room temperature 
for 60 h. The solvent is then removed under reduced pressure and the crude material is 
purified by flash chromatography (CH2Cl2/MeOH 10:0.05) to obtain 10 as a white solid 
(0.062 g, Yield: 92%). 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 7.72 (dd, J= 7.2, 7.2 Hz, 2H), 7.58 (dd, J = 7.2, 2 Hz, 
2H), 7.37 (dd, J= 16, 7.2 Hz, 2H), 7.30 (ddd, J=14.8, 7.2, 1.2 Hz, 2H), 5.37 (br d, J= 2.8 Hz, 
1H), 4.68 (dd, J= 10.8, 5.2 Hz, 1H), 4.57 (dd, J= 10.8, 5.6 Hz, 1H), 4.21 (dd, J= 5.2, 5.6 Hz, 
1H), 3.54 (dd, J=12.8, 4.0 Hz, 2H), 3.44 (ddd, J= 11.6, 11.6, 4.0 Hz, 1H), 2.95 (dd, J= 9.6, 7.2 
Hz, 1H), 2.75 (dd, J= 12.8, 8.4 Hz, 1H), 2.39-2.35 (m, 1H), 2.30-2.09 (m,5H), 1.75 (s, 3H), 
1.85-1.63 (m, 5H), 1.59-1.49 (m, 1H), 1.46-1.39 (m, 4H), 1.35-1.27 (m, 1H), 1.23 (ddd, J= 
13.2, 3.2, 3.2 Hz, 1H), 1.02-0.88 (m, 2H), 0.93 (d, J= 6.8 Hz, 3H), 0.93 (s, 3H), 0.6 (s, 3H).  
 
13C-NMR: (CDCl3, 100 MHz): δ(ppm)= 157.94, 143.97, 143.87, 142.59, 141.69, 141.45, 
141.39, 127.65, 127.62, 127.09, 127.06, 126.66, 124.58, 121.79, 119.99, 119.95, 84.76, 
72.63, 71.73, 66.58, 52.05, 51.05, 49.19, 47.31, 41.78, 41.57, 41.50, 38.21, 36.56, 35.22, 
32.63, 31.35, 31.08, 30.89, 29.00, 28.28, 24.60, 20.26, 18.66, 13.63, 10.23.  
 
ESI-MS: m/z 634.67 [M+ H]+.  
  
[]D
32= -7.5462 (c = 0.067, CHCl3). 
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Synthesis of 11 
 
 
 
To a solution of 7 (0.660 g, 0.001706 mol) in dry CH2Cl2 (18 mL) 4,4’-dithiodibutyric acid 
(0.812 g, 0.003411 mmol), EDC.HCl (0.393 g, 0.002047 mol) and DMAP (0.146 g, 0.001194 
mmol) are added and the reaction mixture is stirred at room temperature for 24 h. HCl 
1M (15 mL) is added and extracted with CH2Cl2 (5x5 mL). The organic layers are dried over 
Na2SO4 and the solvent is removed under reduced pressure. The crude is purified by flash 
chromatography (AcOEt/Hex) to obtain 11 as a colourless oil (0.596 g, Yield: 58%). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 5.12-5.06 (m, 5H), 4.03 (t, J = 6.0 Hz, 2H), 2.74-2.68 
(m, 4H), 2.51-2.40 (m, 4H), 2.07-1.99 (m, 22H), 1.79-1.71 (m, 2H), 1.68 (s, 3H), 1.59 (s, 
15H).  
 
13C-NMR (CDCl3, 75 MHz): δ(ppm)= 178.0, 173.1, 135.1, 134.9, 133.6, 125.1, 124.3, 64.3, 
39.7, 37.8, 37.6, 35.8, 32.6, 32.1, 28.2, 26.8, 26.7, 25.7, 24.3, 23.9, 17.7, 16.0, 15.9.  
 
ESI-MS: m/z 606.2 [M-1]+. 
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Synthesis of 12 
 
 
 
To a solution of 7 (0.100 g, 0.000258 mol) in dry CH2Cl2 (2.5 mL) sebacic acid (0.104 g, 
0.000517 mol), EDC.HCl (0.060 g, 0.000310 mol) and DMAP (0.022 g, 0.000181 mol) are 
added and the reaction mixture is stirred at room temperature for 24 h. HCl 1M (15 mL) is 
added and extracted with CH2Cl2 (5x5 mL). The organic layers are dried over Na2SO4 and 
the solvent is removed under reduced pressure. The crude is purified by flash 
chromatography (AcOEt/Hex 1:3) to obtain 12 as a colourless oil (0.051 g, Yield: 35%). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 5.13-5.06 (m, 5H), 4.02 (t, J = 9.0 Hz, 2H), 2.36-2.25 
(m, 4H), 2.08-1.97 (m, 20H), 1.84-1.59 (m, 22H), 1.30 (bs, 8H).  
 
13C-NMR (CDCl3, 75 MHz): δ(ppm)= 178.9, 173.9, 135.1, 134.9, 1337.7, 125.1, 124.3, 64.0, 
39.7, 35.8, 34.3, 33.8, 29.7, 29.0, 28.2, 26.9, 26.7, 25.6, 24.9, 24.6, 17.7, 16.0.  
 
ESI-MS: m/z 507.3 [M-1]+. 
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Synthesis of 13a 
 
 
 
To a solution of 10 (0.030 g, 0.000047 mol) in CH2Cl2 (1 mL) 11 (0.029 g, 0.000047 mol), 
EDC.HCl (0.011 g, 0.000057 mol) and DMAP (0.005 g, 0.000040 mol) are added and the 
reaction mixture is stirred at room temperature for 24 h. The solvent is then removed 
under reduced pressure and the crude material is purified by flash chromatography 
(CH2Cl2/Hex 8:2) to obtain 13a as a colorless oil (0.030 g, Yield: 52%). 
  
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 7.80-7.68 (m, 2H), 7.60-7.51 (m, 2H), 7.41-7.22 (m, 
4H), 5.45-5.35 (m, 1H), 5.20-5.06 (m, 5H), 4.74-4.50 (m, 2H), 4.25-4.00 (m, 4H), 3.70-3.27 
(m, 2H), 2.97-2.92 (m, 1H), 2.80-2.69 (m, 4H), 2.45-2.40 (m, 4H), 2.38-0.91 (m, 74H).  
 
ESI-MS: m/z 1246.1 [M+Na]+.  
 
[]D
𝟑𝟏 = -4.9062 (c = 0.133, CHCl3). 
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Synthesis of 14a 
 
 
 
To a solution of 10 (0.031 g, 0.000049 mol) in CH2Cl2 (1 mL) 12 (0.028 g, 0.000049 mol), 
EDC.HCl (0.011 g, 0.000058 mol) and DMAP (0.005 g, 0.000041 mol) are added and the 
reaction mixture is stirred at room temperature for 24 h. The solvent is then removed 
under reduced pressure and the crude material is purified by flash chromatography 
(CH2Cl2/Hex) to obtain 14a as a colourless oil (0.027 g, Yield: 47%). 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 7.80-7.65 (m, 2H), 7.75-7.50 (m, 2H), 7.50-7.13 (m, 
4H), 5.45-5.31 (m, 1H), 5.20-5.00 (m, 5H), 4.70 - 4.50 (m, 2H), 4.25-4.13 (m, 1H), 4.10-3.92 
(m, 3H), 3.30-2.75 (m, 2H), 2.-.69 (m, 1H), 2.45-0.67 (m, 88H).  
 
ESI-MS: m/z 1209.3 [M+Na]+. 
 
[]D
𝟑𝟏 = -5.5589 (c = 0.133, CHCl3). 
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Synthesis of 13 
 
 
 
To a solution of 13a (0.030 g, 0.000024 mol) in CH2Cl2 (0.6 mL) diethylamine (0.106 g, 
0.001447 mol) was added and the reaction mixture was stirred at room temperature for 
72 h. The volatiles were then removed under reduced pressure and the crude material 
was purified by flash chromatography (from 100% CH2Cl2 to AcOEt/MeOH 25:1) to obtain 
13 as a colourless oil (0.013 g, Yield: 52%). 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 5.40-5.35 (m, 1H), 5.20-5.03 (m, 5H), 4.70-4.56 (m, 
2H), 4.03 (t, J= 7.1Hz, 2H), 3.51-3.32 (m, 2H), 3.25-3.14 (m, 1H), 2.71 (t, J=7.1 Hz, 4H), 
2.46-2.37 (m, 4H), 2.32-0.81 (m, 76H).  
 
13C-NMR: (CDCl3, 75 MHz, detected signals): δ(ppm)= 172.94, 172.27, 144.25, 142.67, 
140.42, 135.10, 134.45, 133.60, 126.95, 125.19, 125.12, 124.38, 124.36, 134.20, 122.78, 
86.32, 84.67, 73.92, 69.82, 64.62, 64.30, 51.85, 49.05, 41.51, 39.72, 39.64, 39.59, 39.57, 
38.22, 37.84, 37.63, 36.60, 35.76, 33.68, 32.96, 31.03, 29.67, 29.14, 28.90, 28.39, 28.24, 
27.51, 26.84, 26.75, 26.64, 26.57, 24.29, 24.21, 24.16, 19.30, 18.55, 18.42, 17.65, 16.02, 
15.85, 13.69, 13.09, 10.72.  
 
ESI-MS: m/z 1000.9 [M+1]+.  
 
[]D
𝟑𝟏 = -12.0955 (c = 0.660, CHCl3).  
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Synthesis of 14 
 
 
 
To a solution of 14a (0.027 g, 0.000023 mol) in CH2Cl2 (0.6 mL) diethylamine (0.098 g, 
0.001342 mol) was added and the reaction mixture was stirred at room temperature for 
72 h. The volatiles were then removed under reduced pressure and the crude material 
was purified by flash chromatography (from 100% CH2Cl2 to AcOEt/MeOH 25:1) to obtain 
14 as a colourless oil (0.007 g, Yield: 29%). 
 
1H-NMR: (CDCl3, 300 MHz): δ(ppm)= 5.42-5.38 (m, 1H), 5.20- 5.00 (m, 5H), 4.70-4.50 (m, 
2H), 4.02 (t, J= 6.4Hz, 2H), 3.40-3.25 (m, 1H), 3.19-3.11 (m, 1H), 2.79-2.68 (m, 1H), 2.62-
2.48 (m, 1H), 2.45-0.80 (m, 87H). 
 
13C-NMR: (CDCl3, 75 MHz, detected signals): δ(ppm)= 173.87, 173.20, 144.29, 140.51, 
134.96, 133.67, 125.04, 124.37, 124.25, 122.66, 86.34, 73.54, 63.95, 51.86, 49.05, 39.71, 
39.64, 35.77, 34.33, 29.06, 28.24, 26.89, 26.63, 24.96, 18.56, 18.41, 17.65, 16.00, 15.83, 
13.08.  
 
ESI-MS: m/z 965.0 [M+1]+.  
 
[]D
𝟑𝟏 = -17.9880 (c = 0.467, CHCl3). 
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Synthesis of 15 
 
 
 
To a solution of 11 (0.024 g, 0.000494 mol), in dry CH2Cl2 (2.5 mL) EDC.HCl (0.013 g, 
0.000659 mol) and DMAP (0.003 g, 0.000231 mol) are added. Then paclitaxel (0.020 g, 
0.000330 mol) is added and the reaction mixture is stirred at room temperature for 22h. 
HCl 1M (15 mL) is added and extracted with CH2Cl2 (5x5 mL). The organic layers are dried 
over Na2SO4 and the solvent is removed under reduced pressure. The crude is purified by 
flash chromatography (AcOEt/Hex from 1:2 to 1:1) to obtain 15 as a white solid (0.025 g, 
Yield: 65%). 
 
1H-NMR (CDCl3, 400 MHz): δ(ppm)= 8.17 (d, J=7.1Hz, 2H), 7.77 (d, J=7.1 Hz, 2H), 7.63 (t, 
J=7.1 Hz, 1H), 7.56-7.51 (m, 3H), 7.47-7.35 (m, 10H), 6.93 (d, J=9.3 Hz, 1H), 6.32 (s, 1H), 
6.28 (t, J=9.0 Hz, 1H), 6.00 (dd, J=9.2 Hz, J=3.1 Hz, 1H), 5.71 (d, J=7.1 Hz, 1H), 5.53 (d, J=3.1 
Hz, 1H), 5.32 (s, 2H), 5.16-5.10 (m, 5H), 5.00 (d, J=7.6 Hz, 1H), 4.50 (dd, J=10.9 Hz, J=6.6 
Hz, 1H), 4.34 (d, J=8.4 Hz, 1H), 4.23 (d, J=8.4 Hz, 1H), 4.05 (t, J=6.7 Hz, 2H), 3.84 (d, J=7.0 
Hz, 2H), 2.73-2.51 (m, 6H), 2.48 (s, 3H), 2.25 (t, J=7.2 Hz, 2H), 2.25 (s, 3H), 2.22-2.15 (m, 
2H), 2.13-1.87 (m, 20H), 1.79-1.68 (m, 8H), 1.63 (bs, 18H), 1.26 (s, 3H), 1.16 (bs, 3H).  
 
13C-NMR (CDCl3, 100 MHz, detected signals): δ(ppm)= 204.5, 173.6, 172.6, 171.9, 170.5, 
168.7, 167.8, 143.5, 137.7, 135.8, 135.6, 134.4, 134.3, 133.5, 132.7, 130.9, 129.8, 129.4, 
129.2, 127.8, 127.2, 125.8, 125.0, 124.9, 85.1, 81.7, 79.9, 77.1, 76.3, 75.8, 74.7, 72.8, 72.5, 
65.0, 59.2, 53.4, 46.3, 43.9, 40.4, 38.4, 37.8, 36.5, 36.3, 33.3, 32.7, 29.0, 27.6, 27.5, 27.4, 
26.4, 24.9, 24.6, 23.4, 22.8, 21.5, 18.3, 16.7, 16.6, 15.5.  
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ESI-MS: m/z 1465.8 [M+Na]+.  
 
[]D
22= -46.2300 (c = 0.100, CHCl3). 
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Synthesis of 16 
 
 
To a solution of 7 (13 mg, 0.0337 mmol) in dry DMF was added NaH (0.81 mg, 0.0337 
mmol) and the reaction was stirred for 3h. A solution of TAMRA (10 mg, 0.0225 mmol) in 
dry DMF was then added to the mixture. The reaction was stirred in the dark at room 
temperature for 72h. The volatiles were then removed under reduced pressure to afford 
16 after filtration on silica gel.  
 
ESI-MS: m/z 831 [M+1]+; 
MALDI-MS: m/z 830 [M]. 
  
 
 
 
 
 
 
 
3. 4-(1,2-diphenylbut-1-en-1-yl) aniline based 
nanoparticles  
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In this scenario, we moved our interest to new self-assembly inducers with particular 
attention to the ones that possess an antiproliferative activity to make possible the 
obtainment of self-assembling dual drugs. We considered the use of the hydrophobic 
moiety of 4-(1,2-diphenylbut-1-en-1-yl)aniline (Figure 35), a tamoxifen analogue, which 
was recently demonstrated to have antiproliferative activity on different human tumor 
cell lines.134,135  
 
 
Figure 35. Structure of the self-assembly inducer 4-(1,2-diphenylbut-1-en-1-yl)aniline. 
 
The expected self-assembly ability of this structure could derive from the π-stacking 
interactions among the aromatic rings of the adjacent molecules, forming a hydrophobic 
core and exposing the polar moieties toward the aqueous environment.  
We prepared five conjugate compounds using aloin or podophyllotoxin as building blocks 
(Figure 36). Aloin was first selected because of its hydrophilic structure in order to test 
the self-assembly properties of amphiphilic conjugates. Then we moved to 
podophyllotoxin, a lipophilic antiproliferative compound, to prove the ability of 4-(1,2-
diphenylbut-1-en-1-yl)aniline to induce self-assembly also in a totally lipophilic 
conjugate.136  
 
 
Figure 36. Structures of the active compounds aloin and podophyllotoxin. 
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Aloin 
 
Aloin is the major anthraquinone of aloe and characterized as the C-glycoside of aloe-
emodin. Aloin is extracted from different types of Aloe as a mixture of two diasteromers 
named as aloin A and aloin B. Aloin A and B differ only in the configuration at C-10. 
(Figure 37). 
                   
Figure 37. Structure of aloin and Aloe barbadensis. 
 
Recent studies showed aloin to have a certain antitumor activity against murine tumors 
(ascites and solid Ehrlich carcinoma),137 as well as on human breast (T47D) and ovarian 
tumor cell lines.138,139 It was also demonstrated that aloin caused a significant dose-
dependent elevation in the S-phase fraction of breast and ovarian tumor cells, and the 
appearance of cells cycling at a higher ploidy level (4G2M). This indicates that aloin did 
not inhibit DNA synthesis and that cells replicated a full complement of DNA but had 
difficulty in mitosis. In vitro study of aloin on human breast cancer cell lines, without 
(MCF-7) and with (SKBR-3) erbB-2-topoisomerase IIa co-amplification, showed that aloin 
at higher concentrations caused a reduction in the proportion of cells undergoing mitosis 
by induction of apoptosis, inhibition of topoisomerase IIa protein expression, and down-
regulation of cyclin B1 protein expression in MCF-7, whereas erbB-2 protein expression 
was not affected. Topoisomerase IIa protein expression was mildly down-regulated in the 
SKBR-3 cell line at higher concentrations only.140 
Furthermore, in vitro and in vivo studies, reported that repeated treatment of rats with 
aloin at its maximum tolerated dose, unlike doxorubicin, does not affect the heart 
function confirmed by biochemical analyses in the serum and tissue and histological 
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examination of cardiomyocytes by light and transmission electron microscopy. The non-
cardiotoxic effect of aloin was explained due to its strong antioxidant and scavenging 
activities for free radicals and reactive oxygen species, as well as iron-chelating 
potential.141  
 
 
Podophyllotoxin 
 
Podophyllotoxin142 is a naturally occurring lignan isolated from the genera Podophyllum 
(Figure 38). Due to its high toxicity, this compound is currently used only as local antiviral 
agent: in fact, it was found unsuitable for clinical use as an anticancer agent due to its 
toxic side effects. However, its semi-synthetic derivative etoposide is an important 
anticancer drug due to a mechanism of action based on the inhibition of the enzyme 
topoisomerase II. 
   
               
Figure 38. Podophyllotoxin, etoposide and Podophyllum Peltatum. 
 
Podophyllotoxin is able to inhibit the formation of the mitotic spindle: this microtubule 
disruption causes the cell cycle arrest at the G2/M phase and subsequently induces 
apoptosis.143 
In general, the binding behaviour of podophyllotoxin results in the partial unfolding of the 
secondary structure of β-tubulin at the carboxy terminus and prevents polymerization.144  
Semi-synthetic podophyllotoxin derivatives, such as etoposide, are recognized as clinically 
useful drugs against various cancers, including small-cell lung cancer, testicular 
carcinoma, lymphoma and Kaposi’s sarcoma.145 Even if these derivatives possess a 
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superior pharmacological profile and broader therapeutic uses, the major drawback is the 
low water solubility that, for example in the case of etoposide, can cause severe allergic 
reactions. 
 
Synthesis of the conjugates 
 
Four different compounds (Figure 39) have been synthesized according to Scheme 7 and 
Scheme 8.  
 
 
Figure 39. Structures of the four conjugates synthetized. 
 
Aniline 5 was obtained through a McMurry reaction between the commercially available 
propiophenone and 4-aminobenzophenone. Acid 6, derived from aniline 5 and sebacic 
acid (Scheme 7), was used for the preparation of compound 1 (as an inseparable mixture 
of diastereomers at position 10) and 4 via a condensation reaction using a coupling agent.  
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Scheme 7. Preparation of conjugates 1 and 4. 
 
The obtainment of single acylation of aloin resulted tricky and after unsuccessful chemical 
attempts we considered the use of an enzyme-controlled regioselective reaction.146 
Intermediates 7 and 8 were prepared via enzyme-controlled procedures and subjected to 
chemical acylation in the presence of EDC or HATU to give 2 and 3, as inseparable 
mixtures of diastereomers (Scheme 8). 
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Scheme 8. Preparation of conjugates 3 and 4. 
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Nanoparticles characterization 
 
Next, the ability of the obtained compounds to form NPs was investigated. Four different 
nanosuspensions were prepared by a dropwise addition of an organic solution of the 
compounds to ultrapure water and by the subsequent removal of the organic solvent 
under reduced pressure. All the conjugates, except 3, seemed to self-assemble, and the 
resulting homogeneous suspensions were characterized by DLS, TEM and nanoparticle 
tracking analysis (NanoSight).147 
DLS measurements (Table 9) gave a first confirmation of the success of the process: as 
indicated by the low values of polydispersity index (PDI < 0.2), compounds 1, 2 and 4 
were able to give monodisperse suspensions of NPs, with hydrodynamic diameters in the 
range of 80–140 nm. These results appear valuable considering that NPs with diameters 
of about 100 nm were demonstrated to show optimal behaviour in terms of both cellular 
uptake and elimination properties.  
Zeta potential values were negative (<−20.0 mV) for all the nanoassemblies in a range of 
pH between 4 and 7.4. These values suggest that the electrostatic repulsion contributes 
to the colloidal stability of the suspension.  
 
Compound 
Mean Diameter (nm) 
DLS 
Mean diameter (nm) 
TEM 
Z potential (mV) 
1 85.93 ± 2.76 69.30 ± 8.05 -23.9 ± 0.36 
2 105.2 ± 10.5 75.72 ± 9.50 -23.0 ± 0.50 
4 133.4 ± 9.1 114.3 ± 23.4 -29.8 ± 0.32 
Table 9. Size and zeta potential of the nanosuspensions. 
 
TEM images (Figure 40) confirmed the uniformity of NP size and showed the NPs to have 
a spherical shape. 
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Figure 40. TEM micrographs of nanoparticles formed by self-assembly of compound 1, compound 2 and 
compound 4. All samples were stained with uranyl acetate solution. In all the panels scale bar represents 100 
nm. 
In order to get more information about the newly formed nanoassemblies, nanoparticle 
tracking analysis was performed by NanoSight technology (Table 10). The direct analysis 
provided sample concentration in terms of number of NPs per volume unit, which was 
then exploited, together with the concentration and the molecular weight of the 
conjugates, to derive the number of molecules self-assembled in one particle.  
Compound 
Concentration  
(NPs mL-1) 
Molecule/NPs 
1 8,73 × 1011 5,11 × 108 
2 4,01 x 1011 1,95 x 109 
4 3,71 x 1011 1,66 x 109 
 
Table 10. Nanoparticle Tracking Analysis (NTA by NanoSight) quantification of nanoconjugates in suspension. 
Derived from NTA concentration calculated as: (Cm/Cn) x (1/MW) x NA. Cm: concentration in mass (g mL−1). 
Cn: concentration in number (number of NPs mL−1). MW: molecular weight of the compound. NA: 
Avogadro’s constant.  
 
In addition, UV-absorbance measurements showed a red shift in the spectra of the 
nanoformulated compounds, suggesting that π-stacking contributed significantly to the 
stability of NPs.   
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In vitro evaluation 
 
The antiproliferative activities of compounds 1–4 and of the corresponding NPs were 
evaluated on two human tumor cell lines, HeLa and HepG2 (Table 11).  
 
 
 
 
 
 
 
 
 
 
 
Table 11. Cell growth inhibition (GI50) of the obtained conjugates (1–4) and of the corresponding 
nanoparticles (1-, 2- and 4-NP) on HeLa (human cervix adenocarcinoma cells) and HepG2 (human 
hepatocellular carcinoma). GI50 values are the concentration of tested agent inducing 50% reduction in cell 
number compared to control cultures after 72 h of incubation. 
 
In detail, the GI50 values indicate for compounds 1 and 2 that the corresponding 
nanosuspensions (1-NP and 2-NP) maintain the biological profile of the native conjugates. 
Interestingly, for 2 and 2-NP the ability to inhibit cell growth is detectable and 
comparable on both cell lines and it is appreciably higher than the antiproliferative 
activity of aloin itself. In this connection, a crucial role seems to be played by the increase 
in lipophilicity due to the conjugation of the aloin with the lipid moiety containing the 4-
(1,2-diphenylbut-1-en-1-yl)aniline, that could allow a more efficient cell uptake. This 
hypothesis is supported by previous studies demonstrating a significant lower absorption 
percentage of aloin with respect to aloe-emodin, in a Caco-2 cell culture model and in 
everted gut sac.148 
Compound GI50 (µM) 
 HeLa HepG2 
Podophyllotoxin  0.0808 0.123 
Aloin > 30 > 30 
1 > 30 > 30 
1-NP > 30 > 30 
2 12.7 15.9 
2-NP 11.9 10.6 
3 > 30 > 30 
4 0.39 1.17 
4-NP 9.75 9.0 
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As regards conjugate 4, it exerts the most significant cytotoxic effect, with GI50 values in 
the low micromolar range; nevertheless, the corresponding nanoparticle 4-NP exhibited a 
GI50 value notably higher, indicating a decrease in the antiproliferative effect. It could be 
hypothesised that for 4-NP the disassembling is not very efficient or it occurs slowly as to 
lead to a lower cellular concentration of the parental drug.  
In conclusion we tested the ability of 4-(1,2-diphenylbut-1-en-1- yl)aniline to induce self-
assembly on different types of conjugates containing aloin or podophyllotoxin. We 
demonstrated that conjugates 1, 2 and 4 are able to self-assemble in spherical NPs, 
confirming the propensity of 4-(1,2-diphenylbut-1-en-1-yl )aniline to induce self-assembly 
both when incorporated into amphiphilic and lipophilic conjugates. The obtained 
nanoformulations showed a diameter of about 100 nm and exhibited negative ζ-potential 
values from −30 to −20 mV, best suited for future in vivo testing. Nevertheless, under our 
experimental conditions compound 3 did not exhibit the same self-assembling behaviour, 
underlying the importance of testing the self-assembly properties of each new conjugate. 
Conjugates 2 and 4 and the corresponding NPs demonstrated a certain antiproliferative 
activity against different cell lines and in one case (compound 2) the activity of the 
conjugate was maintained when nanoformulated. Moreover, both 2 and 2-NP appeared 
more active than the native aloin, suggesting a beneficial effect of amphiphilic 
conjugation resulting from the chemical derivatization and formulation.  
The reported results open the possibility to prepare a plethora of 4-(1,2-diphenylbut-1-
en-1-yl)aniline based conjugates containing different anticancer drugs as building blocks 
and suitable linkers to induce drug release after cell internalization.  
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General 
 
Thin-layer chromatography (TLC) was performed on Merck precoated 60F254 plates. 
Reactions were monitored by TLC on silica gel, with detection by Uv light ( = 254 nm) or 
by charring with 1% permanganate solution. Flash chromatography was performed using 
Silica gel (240-400 Mesh, Merck). NMR spectra were recordered with Brucker 300 and 
400 MHz spectrometers. Chemical shifts are reported in parts per million () downfield 
from tetramethylsilane (TMS). EI mass spectra were recorded at an ionizing voltage of 6 
kEv on a VG 70-70 EQ. ESI mass spectra were recorded on FT-ICR APEXII. Specific rotations 
were measured with a P-1030-Jasco polarimeter with 10 cm optical path cells and 1 ml 
capacity (Na lamp,  = 589 nm). Microwave assisted reaction were performed with Emrys 
Creator single-mode (power range 0-400 W from magnetron at 2.45 GHz). 
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Synthesis of 5 
 
 
To a cold (-10°C) suspension of Ζn (1.204 g, 18.124 mmol) in ΤНF (18 mL), TiCl4 (0.82 mL, 
7.502 mmol) is dropwise added and the mixture is stirred for 10 min and then it is 
refluxed for 2 h. Then, a solution of 4-aminobenzophenone (0.371 g, 1.911 mmol) and 
propiophenone (0.281 g, 2.103 mmol) in ΤНF (37 mL) is added to the cooled suspension of 
the titanium reagent at 0°C, and the reaction mixture is refluxed for 2.5 h. After the 
completion of the reaction, the reaction mixture is cooled to rt and poured into a 10% aq 
K2CO3 solution (15 mL). Vigorous stirring is maintained for 5 min, and the dispersed 
insoluble material is removed by vacuum filtration on celite. The organic layer is 
separated and the aqueous layer is extracted with AcOEt. The organic layers are washed 
with water and brine, dried with Na2SO4, filtered and evaporated. The residue is purified 
by flash column chromatography (Hex/AcOEt 8:2) and after evaporation of the solvent, 
product 5 is obtained as white amorphous solid (45% yield).  
 
 1H-NMR (CDCl3, 300 MHz): δ(ppm)= 7.37 (t, J=7.2 Hz, 2H), 7.31-7.27 (m, 3H), 7.23-7.13 
(m, 5H), 6.69 (d, J=8.8 Hz, 2H), 6.40 (d, J=8.8 Hz, 2H), 2.48 (q, J=7.6 Hz, 2H), 0.950 (t, J=7.6 
Hz, 3H). 
13C-NMR (CDCl3, 75 MHz): δ(ppm)= 144.7, 144.0, 143.5, 141.4, 139.4, 134.7, 132.3, 130.4, 
130.1, 128.6, 128.4, 127.0, 126.5, 115.2, 29.55, 13.99;  
ESI-MS: m/z 300.42 (M + H)+.  
Anal. Calcd for C22H21N: C, 88.25; H, 7.07; N, 4.68. Found: C, 87.35; H, 6.87; N, 4.50. 
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Synthesis of 6 
  
 
 
To a solution of sebacic acid (0.255 g, 1.263 mmol) in dry THF (20 mL) HATU (0.527 g, 
1.386 mmol) and DIPEA (0.326 g, 2.523 mmol) are added and the reaction mixture is 
stirred for 30 minutes. Then 5 (0.378 g, 1.265 mmol) is added and the reaction mixture is 
stirred at rt overnight. The solvent is removed under reduced pressure, AcOEt is added 
and it is washed with water and brine. The organic layer is then dried over Na2SO4 and 
concentrated under reduced pressure. The crude is purified by flash chromatography 
(AcOEt/Hex 4:6) to obtain pure 6 (0.476 g, Yield: 78%).  
 
1H-NMR(CDCl3, 300 MHz): δ(ppm)= 7.33-7.02 (m, 12H), 6.80 (d, J=7.8, 2H), 4.78 (bs, 1H), 
2.43  (q,  J = 7.6  Hz, 2H), 2.30 ( t, J=7.7  Hz, 2H), 2.25 (t, J=7.5 Hz, 2H), 1.75-1.55 (m, 4H), 
1.40-1.25 (m, 8H), 0.92  (t,  J =7.7  Hz).  
 
13C-NMR (CDCl3, 75 MHz): δ(ppm)= 175.3, 174.6, 145.1, 143.2, 143.1, 141.3, 139.7, 135.4, 
131.9, 129.6, 129.4, 128.2, 127.7, 127.3, 126.3, 116.1, 37.58, 34.98, 31.80, 30.81, 26.96, 
26.22, 13.60. 
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Synthesis of 1  
 
To a solution of 6 (0.085 g, 0.176 mmol) in CH2Cl2 (10 mL) DMAP (0.032 g, 0.262 mmol) 
and EDC∙HCl (0.050 g, 0.262 mmol) are added and the reaction mixture is stirred for 30 
minutes. Then aloin (0.091 g, 0.269 mmol) is added and the reaction mixture is stirred at 
40°C overnight. The solvent is removed under reduced  pressure to give 1 without further 
purification (0.021 g, Yield: 8%). 
 
1H-NMR (CD3OD, 400 MHz): δ(ppm)= 7.58-7.47 (m, 2H), 7.37-7.34 (m, 3H), 7.30-6.95 (m, 
24H), 6.89-6.87 (m, 1H), 6.81-6.79 (m, 3H), 5.16-5.13 (m, 2H), 4.90-4.86 (m, 1H), 4.67-4.64 
(m, 1H), 3.68-3.41 (m, 4H), 3.13-3.04 (m, 2H), 2.51-2.25 (m, 12H), 1.74-1.52 (m, 8H), 1.31-
1.25 (m, 16H), 0.92 (t, J=7.3 Hz, 6H). 
 
13C-NMR (CD3OD, 100 MHz): δ(ppm)= 194.0, 174.5, 173.8, 173.1, 162.0, 161.8, 145.2, 
144.9, 144.7, 143.4, 142.2, 141.9, 138.8, 138.4, 136.2, 135.9, 130.8, 130.4, 129.4, 129.1, 
127.9, 127.6, 127.5, 127.0, 126.4, 125.9, 119.7, 118.7, 117.3, 116.9, 85.25, 85.06, 80.33, 
79.31, 68.80, 64.79, 61.49, 44.40, 33.74, 33.58, 28.76, 28.52, 25.42, 24.62, 24.43, 12.42. 
 
ESI-MS = 1372.3 (M+Na+)+ 
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Synthesis of 8   
 
 
To a solution of aloin (100 mg, 0.24 mmol) in dry acetone (15 mL) divinyl dodecanedioate 
(101 mg, 0.36 mmol) and Novozyme 435 (30 mg) are added. The resulting heterogeneous 
mixture is incubated at 45 °C and 210 rpm for 48h. After that, 5 μL water are added to the 
mixture which is incubated again for additional 2 h, checking the formation of the target 
acid by TLC (CHCl3/MeOH/HCOOH = 8:2:0.1, UV). The crude mixture is then filtered, 
concentrated in vacuo and purified by flash column chromatography on silica gel 
(AcOEt/MeOH/H2O = 9.5:0.5:0.1) affording the purified product 8 as a yellow oil (60 mg, 
40%).  
 
1H-NMR (CD3OD, 400 MHz): δ(ppm)= 7.50 (ddd, J=8.3, 7.5, 6.3 Hz, 1H), 7.06 (q, J=6.0 Hz, 
2H), 6.89-6.84 (m, 2H), 5.16 (d, J=3.7 Hz, 2H), 4.59 (d, J=1.5 Hz, 1H), 3.58 (dd, J=11.7, 1.9 
Hz, 1H), 3.43-3.39 (m, 2H), 3.33 (dt, J=3.3, 1.6 Hz, 2H), 3.28 (t, J=8.6 Hz, 1H), 3.03-2.97 (m, 
1H), 2.94-2.89 (m, 2H), 2.47-2.37 (m, 4H), 1.70-1.58 (m, 4H), 1.29 (bs, 12H). 
 
13C-NMR (CD3OD, 100 MHz): δ(ppm)= 194.1, 173.68, 173.60, 170.9, 161.84, 161.75, 
161.62, 161.59, 145.5, 145.08, 145.04, 144.4, 142.1, 135.8, 135.0, 119.9, 118.60, 118.59, 
117.5, 117.24, 117.22, 116.88, 116.70, 115.8, 115.5, 114.1, 113.9, 85.0, 80.30, 80.20, 
78.55, 78.53, 70.62, 70.53, 70.46, 64.74, 64.71, 61.89, 61.85, 44.5, 33.6, 33.2, 29.08, 
29.03, 28.91, 28.88, 28.74, 28.65, 24.7, 24.3. 
 
ESI-MS = 653.3 (M+Na+)+.  
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Synthesis of 3  
 
 
To a solution of 8 (0.080 g, 0.130 mmol) in THF (30 mL) HATU (0.050 g, 0.130 mmol) and 
DIPEA (0.034 g, 0.266 mmol) are added and the reaction mixture is stirred for 30 minutes. 
Then 5 (0.039 g, 0.130 mmol) is added and the reaction mixture was stirred at rt for 72h. 
The solvent is removed under reduced  pressure to obtain crude 3. The crude is purified 
by flash chromatography (CH2Cl2/MeOH) to obtain pure 3 (0.077 g Yield: 65%).  
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 7.45-6.76 (m, 19H), 4.84-4.64 (m, 2H), 4.53 (m, 1H), 
4.12-4.08 (m, 1H), 3.74-3.68 (m, 2H), 3.20-2.80 (m, 4H), 2.41 (q, J=7.4 Hz, 2H), 2.31-2.26 
(m, 2H), 2.15-2.12 (m, 2H), 1.70-1.57 (m, 2H), 1.53-1.42 (m, 2H), 1.32-1.24 (m, 12H), 0.89 
(t, J=7.4 Hz, 3H). 
 
13C-NMR (CDCl3, 75  MHz): δ(ppm)= 195.8, 175.5, 174.9, 163.3, 163.0, 147.4, 145.1, 143.8, 
143.6, 142.8, 140.5, 140.1, 137.9, 132.5, 132.2, 131.2, 130.8, 129.6, 129.3, 128.1, 127.6, 
121.6, 120.4, 119.5, 118.8, 118.2, 114.9, 114.4, 86.31, 80.09, 79.29, 71.82, 71.47, 64.85, 
45.83, 38.33, 35.12, 30.85, 30.51, 27.26, 26.16, 13.50. 
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Synthesis of 7   
 
 
Aloin (100 mg, 0.24 mmol) and vinyl acetate (33 μL, 0.36 mmol) are dissolved in 15 mL of 
dry acetone under nitrogen atmosphere. Molecular sieves 4Å (30 mg) and lipase PS 
supported on Celite® (80 mg, 1 % w / w lipase / celite) are then added to the resulting 
solution which is incubated at 45 °C and 210 rpm for 48 h. After that, the formation of the 
desired product is checked by TLC (CHCl3/MeOH/HCOOH = 8:2:0.1, UV) and the crude 
mixture filtered, concentrated in vacuo and purified by flash column chromatography on 
silica gel (AcOEt/MeOH/H2O = 9.5:0.5:0.1), affording the purified product 7 as a yellow 
solid (85 mg, 80%).  
 
1H-NMR (CD3OD, 400 MHz): δ(ppm)= 7.47 (ddd, J=8.3, 7.6, 5.8 Hz, 1H), 7.04-7.00 (m, 2H), 
6.86-6.81 (m, 2H), 5.16 (d, J=3.6 Hz, 2H), 4.50 (d, J=1.9 Hz, 1H), 3.59-3.55 (m, 1H), 3.42-
3.37 (m, 2H), 3.29-3.25 (m, 1H), 3.00-2.88 (m, 3H), 2.17 (s, 1H), 2.15 (s, 2H). 
 
13C-NMR (CD3OD, 100 MHz): δ(ppm)= 194.0, 171.6, 171.13, 171.03, 161.77, 161.69, 
161.55, 161.51, 145.4, 145.01, 144.88, 144.2, 142.0, 141.6, 135.7, 135.0, 119.9, 118.58, 
118.51, 117.4, 117.2, 116.82, 116.63, 115.7, 115.5, 114.1, 113.8, 85.18, 85.01, 80.26, 
80.17, 78.53, 78.50, 70.60, 70.58, 70.50, 70.46, 64.96, 64.91, 61.88, 61.83, 60.2, 44.45, 
44.38, 19.50, 19.44, 13.1. 
 
ESI-MS = 483.1 (M+Na+)+. 
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Synthesis of 2  
 
 
 
To a solution of 6 (0.080 g, 0.166 mmol) in CH2Cl2 (18 mL) are added EDC∙HCl (0.038 g, 
0.199 mmol) and DMAP (0.025 g, 0.199 mmol) and the reaction mixture is stirred for 30 
minutes. Then 7 (0.076 g, 0.166 mmol) is added and the reaction mixture is stirred at rt 
for 72h. The solvent is removed under reduced pressure to obtain crude 2. The crude is 
purified by flash chromatography (CH2Cl2/MeOH) to obtain pure 2 (0.030 g Yield: 20%).  
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 7.53-7.50 (m, 1H), 7.38-7.35 (m, 2H), 7.30-7.09 (m, 
12H), 6.90-6.88 (m, 2H), 6.80 (d, J=8.4 Hz, 2H), 5.15 (d, J=3.6 Hz, 2H), 4.88 (m, 1H), 4.65 (s, 
1H), 3.56 (d, J=12 Hz, 1H), 3.53 (d, J=9.6 Hz, 1H), 3.44 (dd, J=12, 5.2 Hz, 1H), 3.12-3.01 (m, 
3H), 2.47 (q, J=7.6 Hz, 2H), 2.37 (t, J=7.2 Hz, 2H), 2.31-2.26 (m, 2H), 2.16 (s, 3H), 1.67-1.57 
(m, 4H), 1.37-1.27 (m, 8H), 0.924 (t, J=7.2 Hz, 3H). 
 
13C-NMR (CDCl3, 75 MHz): δ(ppm)=  194.7, 174.8, 173.9, 173.8, 162.3, 162.2, 145.8, 144.1, 
142.8, 142.6, 142.0, 139.4, 139.1, 136.9, 135.8, 131.4, 130.1, 129.7, 128.5, 128.2, 127.0, 
126.8, 119.4, 119.1, 117.9, 116.3, 114.6, 85.70, 81.06, 79.93, 69.60, 65.60, 62.13, 45.03, 
37.19, 34.36, 29.42, 29.16, 26.08, 25.08, 20.03, 13.06. 
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Synthesis of 4  
 
To a solution of 6 (0.059 g, 0.122 mmol) in dry CH2Cl2 (10 mL), EDC·HCl (0.028, g, 0.147 
mmol) and DMAP (0.011 g, 0.086 mmol) are added. Then, aloin (0.051 g, 0.122  mmol) is 
added in the reaction mixture and stirred at rt for  5 h. HCl 1M (9 mL) is then added and 
the aqueous phase is washed with AcOEt (4 x 8 mL). The combined organic extracts are 
dried over Na2SO4 and evaporated under reduced pressure.  The crude is purified by flash 
chromatography (AcOEt/Hex) to provide 4 (0.086 g, 80 %) as an orange solid. 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 7.38-7.09 (m, 12H), 6.80 (d,  J=8.5 Hz, 2H), 6.78 (s, 
1H), 6.53 (s, 1H), 6.37 (s, 2H), 5.95 (d, J=4.5 Hz, 2H), 5.88 (d,  J=8.9 Hz, 1H), 4.59 (d, J=4.0, 
1H), 4.36-4.31 (m, 1H), 4.22-4.18 (m, 1H), 3.78 (s, 3H), 3.72 (s, 6H), 2.92 (dd, J=14, 4.5 Hz, 
1H), 2.82-2.77 (m, 1H), 2.55-2.29 (m, 4H), 2.22 (t, J=7.5 Hz, 2H), 1.81-1.51 (m, 4H), 1.48-
1.18 (m, 8H), 0.93 (t, J=7.7 Hz, 3H). 
 
13C-NMR (CDCl3, 75 MHz): δ(ppm)= 174.9, 174.4, 171.8, 153.3, 148.8, 148.3, 144.1, 142.9, 
142.7, 139.5, 138.8, 137.7, 136.4, 135.5, 133.0, 132.0, 130.3, 130.2, 129.0, 128.8, 128.6, 
127.3, 126.8, 119.2, 110.4, 108.7, 107.8, 102.3, 74.06, 72.15, 61.43, 56.76, 46.30, 44.40, 
39.53, 38.27, 35.03, 29.81, 26.16, 25.69, 14.22. 
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The need of improving the drug release of the systems described in the previous chapters 
prompted us to consider the synthesis of a new class of conjugates. These conjugates are 
characterized by the presence of a self-immolative linker able to improve the drug release 
in particular conditions.149 
 
Self-immolative linkers 
 
The strategy of the self-immolative linker consists of connecting the drug and the carrier 
in a cleavable way (Figure 41 a) or by attaching a triggering moiety that, upon specific 
conditions or in the presence of specific enzymes, is able to induce a cascade that ends 
with release of the drug (Figure 41 b). In the latter case, the linker forms a scissible bond 
with a protecting group and a stable bond with the drug unit, that becomes labile upon 
removal of the protecting group, resulting in a rapid disassembly of the three 
components (self-immolative elimination). 
 
 
 
Figure 41. Different approaches for drug release. 
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Some examples of self-immolative linkers including their mechanism of drug release are 
summarized in Table 12: 
 
Linker Reaction type Release mechanism 
 
1,6-benzyl 
elimination 
 
 
1,4-benzyl 
elimination 
 
 
1,8-elimination 
 
 
β-elimination 
 
 
Cyclization 
(lactonization) 
 
 
Cyclization 
(lactonization) 
 
 
Cyclization 
 
 
Table 12. Self-immolative linkers and their mechanism of drug release. 
 = Protecting group; = Drug unit; X, Z = O, NH   
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The evolution of self-immolative linker technology has led to self-immolative systems 
capable of amplified release, such as dendrimers (Figure 42 a) and polymers (Figure 42 b). 
 
 
 
Figure 42. Dendrimer and polymer disassembly. 
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In order to guarantee the release of the drug inside the cell, we designed a new self-
immolative linker.  
This new linker is covalently bonded to a self-assembly (SA) inducer, able to cause the 
formation of nanoparticles, and it is characterized by the presence of a labile bond 
(Scheme 9). The labile bond is the one with the acetyl group on the phenolic oxygen and 
it is cleaved by a lipase inducing the release of the free drug.   
 
Scheme 9. Mechanism of drug release of the self-immolatice linker. 
The general structure of the conjugates synthetized is reported is Figure 43: the self-
assembly inducer is bonded to the self-immolative linker through a 10-atom chain. We 
decided to synthetized both the compound characterized by a simple carbon chain and 
the one characterized by the presence of a disulphide moiety, in order to study the role of 
both the parts of the molecule. 
 
Figure 43. General structure of the conjugates. 
The detailed structure of the conjugates synthetized is reported below (Figure 44). 
  
Figure 44. Structures of the conjugates characterized by the presence of the self-immolative linker. 
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We decided to prepare a class of bivalent compounds in which also the self-assembly 
inducer has some antiproliferative activity and we selected 4-(1,2-diphenylbut-1-en-1-
yl)aniline (Chapter 4) as self-assembly inducer and desacetylthiocolchicine as anticancer 
drug. 
Colchicine 
 
Colchicine is a well-known alkaloid from Colchicum autumnale and Gloriosa superba 
(Figure 45). It interferes with microtubule growth and, therefore, affects mitosis and 
other microtubule dependent functions.150 
 
                 
Figure 45. Structure of Colchicine and Colchium autumnale and Gloriosa superba.     
 
Colchicine is one of the oldest drugs still in use for the treatment of gout and amyloidosis 
of familial Mediterranean fever.151 Although colchicine is a potent antimitotic agent, its 
medicinal uses are limited due to its high toxicity. Virtually all of its therapeutic and toxic 
effects are believed to be a consequence of its interaction with tubulin. For these 
reasons, colchicine has become an attractive molecule for the medicinal chemists in 
pursuit of less toxic and more selective analogs which bind to tubulin. 
Structurally, colchicine can be divided into three parts (Figure 45): a trimethoxybenzene 
ring moiety (A), a seven-membered ring with a side chain at C(7) (B), and a tropolone ring 
(C). Previous studies suggested that the interaction between colchicinoids and tubulin 
was stereoselective and mainly attributed to the configuration and conformation of the 
biaryl system composed of the trimethoxyphenyl ring and tropolonic ring.152,153,154  
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Colchicinoids with an aS-configured biaryl system155 bind readily to tubulin, while those 
with an aR configuration bind poorly. Moreover, it has been proposed that in addition to 
the effect of the C(1) substituents on the biaryl configuration, the C(7) side chain could 
also influence the binding rate of colchicinoids to tubulin as well as the configuration of 
the colchicinoids through steric effects.156  
 
Colchicine interaction with proteins  
Colchicine interacts mainly with three known proteins: tubulin, cytochrome P450 3A4 
(CYP3A4) and P-glycoprotein (P-gp). 
Tubulin: Microtubules are composed of two structurally similar protein subunits, α-
tubulin and β-tubulin, which are spherical proteins composed of ∼440 amino acids 
(50kDa).157 Colchicine binds at the interface between the α and β subunits of tubulin 
within the heterodimer by H-bonding (with the Cys241 residue of β-tubulin) and 
hydrophobic interactions158,159 (Figure 46). Colchicine binds with high affinity to tubulin 
that can become copolymerized into microtubules. The antiproliferative action of 
colchicine involves the capacity of the tubulin–colchicine complex to bind to the ends of 
microtubules and actually prevent the elongation of the microtubule polymer.160 Because 
of this effect, colchicine effectively functions as a ‘mitotic poison’ or spindle poison as 
tubulin availability is essential to mitosis. 
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Figure 46. (a)Crystal structure of αβ-tubulin heterodimers showing the binding sites of colchicine.(b) 
Interactions of colchicine with the colchicine-binding site of tubulin. 
 
To discover colchicine-based anticancer drugs, the tubulin–colchicine domain 
computational stimulation has been investigated using the crystal structures of colchicine 
and its semisynthetics.161 The thiocolchicine (Figure 47) analogues were more potent than 
the colchicine analogues in the tubulin polymerization assay.162 Different semisynthetic 
thiocolchicine hybrids such as paclitaxel–thiocolchicine, thiocolchicine–podophyllotoxin 
and vindoline–thiocolchicine as well as thiocolchicine dimers and were successfully tested 
as multifunctional tubulin inhibitors.163,164,165 
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Figure 47. Structure of thiocolchicine. 
Cytochrome P450 3A4: In the occurrence of several drug–drug interactions, drug 
metabolism through the cytochrome P450 (CYP450) system has emerged as a significant 
determinant. CYP450 belongs to the hemethiolate class of enzymes that catalyse the 
oxidation of a wide variety of xenobiotics and pharmaceutical agents. CYP450 enzymes 
metabolize the majority of marketed drugs; thus, it is important to characterize the 
interactions of potential new therapies with members of this enzyme.  
In humans, colchicine metabolism has not yet been investigated. In vitro experiments 
using primary human hepatocyte cultures or hepatic microsomes and in vivo animal 
studies are the only available data sources. Its metabolic clearance is chiefly dependent 
on the metabolic activity and free plasma fraction on the enzymes. However, the blood 
flow has a limited influence over it. It has been established by various authors that 
colchicine undergoes oxidative demethylation into 2-, 3- and 10-DMC.166 Recently, 
colchicine derivatives have been tested for the inhibition of five major CYP450 
isoenzymes. The results indicate that these compounds showed moderate or very low 
inhibition of CYP450 enzymes, and thus does not have CYP liability.167  
 
P-glycoprotein: P-gp is an ATP-dependent phosphoglycoprotein that is located in the cell 
membrane and interacts with various drugs. P-gp affects the absorption, distribution and 
elimination of its substrates, including colchicine.168  
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Overexpression of P-gp decreases intracellular drug levels, as a result limiting drug 
cytotoxicity. In case of colchicine, the development of tumour resistance mainly occurs 
through its P-gp induction activity, causing its active efflux from tumour cells, and 
increase in the expression of βIII tubulin isotype.169,170 Colchicine is a substrate of the P-gp 
efflux pump and it activates this pump by inducing conformational change. The P-gp 
substrate and induction liability of colchicine restricts its use in combination with other 
cytotoxic drugs that are P-gp substrates such as vinblastine, doxorubicin and paclitaxel.171 
To overcome P-gp-mediated resistance in colchicine, it has been shown that its N-
benzylated derivative maintained similar levels of cytotoxic activity in resistant A2780AD 
ovarian carcinoma cells that are known to overexpress the ABCB1 (P-gp) drug 
transporter.172 
The features described above provide promise for the rational design of colchicine 
analogs. Much work has been done with thiocolchicine, which acts similarly to 
colchicine173 but it is stable toward acid and it is therefore a preferred compound in 
structure-activity studies.174 Among thiocolchicine derivatives, N-deacetyl thiocolchicine 
was tested in vitro on human breast cancer cell line (MDR negative MDA-MB 231), 
showing a significant antiploriferative activity.175 
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Synthesis of the conjugates 
 
We started the preparation of the conjugates by synthetizing the self-immolative moiety. 
The first synthetic pathway is reported in Scheme 10. The commercially available 4-
hydroxybenzaldehyde was alkylated with allylbromide in the presence of potassium 
carbonate and potassium iodide to obtain ether 3 that was subsequently reduced to 
alcohol 4 using NaBH4. The formation of carbonate 5 was achieved in good yield by 
treating compound 5 with 4-nitrophenylchloroformate. Unfortunately, the microwave-
assisted Claisen rearrangement was not successful and we were not able to isolate the 
desired product. 
 
Scheme 10. First synthetic pathway for the self-immolative linker. 
We decided to consider an alternative synthetic pathway (Scheme 11), changing the 
reactions sequence. Compound 4 was first submitted to a microwave-assisted Claisen 
rearrangement to obtain alcohol 6 in good yield. The following acylation with acetic 
anhydride and reduction with NaBH4 led to the obtainment of compound 8, which was 
reacted with 4-nitrophenylchloroformate to achieve carbonate 9. Then, a hydroboration 
reaction, followed by a basic work up (aq. NaOH), was performed to achieve a formal 
anti-Markovnikov addition on the double bond and get the final self-immolative linker 10. 
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Scheme 11. Alternative synthetic pathway. 
The self-immolative linker 10 is then reacted with the anticancer compound N-
desacetylthiocolchicine which was previously synthetized (Scheme 12) following a 
reported procedure.176 
 
 
 Scheme 12. Preparation of N-desacetylthiocolchicine. 
Unfortunately, the reaction between the amino group of N-desacetylthiocolchicine and 
the carbonate moiety of compound 10 was not effective and we didn’t manage to obtain 
the desired product (Scheme 13). 
 
 
Scheme 13. Drug-conjugation reaction. 
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Therefore, we decided to functionalize the amino moiety of the N-desacetylthiocolchicine 
with glycine in order to link the anticancer compound to our linker through a less 
hindered amine. For this aim, compound 11 was prepared according to Scheme 14. 
 
 
Scheme 14. Synthesis of compound 11. 
This approach was successful to obtain the desired intermediate 12 (Scheme 15). 
 
 
Scheme 15.  Drug-conjugation reaction. 
The final reaction between compound 12 and the acids 13a,b (Chapter 4) in the presence 
of EDC and DMAP lead to the obtainment of the final esters 1 and 2 (Scheme 16).  
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Scheme 16. Synthesis of conjugates 1 and 2.  
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Lipase-induced drug release  
 
The efficacy of the release of the parental drug has been evaluated incubating our final 
compounds in the presence of different types of lipases (Scheme 17) and analysing the 
reaction mixtures by reverse-phase HPLC. 
 
Scheme 17. Lipase-mediated drug release. 
 
In the case of compound 1, the best result was obtained using porcine pancreatic lipase 
which gave 88% of hydrolysis and we were able to observe by HPLC-MS the peaks 
corresponding to the released desacetylthiocolchicine and the 4-(1,2-diphenylbut-1-en-1-
yl)aniline. 
The higher conversion of compound 2 was instead achieved using lipase PS @Celite and 
also in this case we confirmed by HPLC-MS the release of the two active compounds 
demonstrating the ability of the conjugates to release the two active moiety. 
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Nanoparticles characterization 
 
Next, the ability of the obtained compounds 1 and 2 to form NPs was investigated. Two 
different nanosuspensions were prepared by a dropwise addition of an organic solution 
of the compounds to ultrapure water and by the subsequent removal of the organic 
solvent under reduced pressure. Both the conjugates seemed to self-assemble, and the 
resulting homogeneous suspensions were characterized by DLS. 
DLS measurements (Table 13) gave a first confirmation of the success of the process: 
compounds 1 and 2 were able to give monodisperse suspensions of NPs, with 
hydrodynamic diameters in the range of 280–320 nm.  
Zeta potential value was negative for compound 1 suggesting that the electrostatic 
repulsion contributes to the colloidal stability of the suspension.  
Compound Mean Diameter (nm) Z potential (mV) 
1 280.1 ± 13.8 -15.1 ± 2.24 
2 312.8 ± 36.6 n.d. 
Table 13.  Nanoparticles characterization. 
 
Currently the biological activity of the conjugates and the corresponding nanoparticles on 
different types of cancer cells is under investigation.  
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General 
 
Thin-layer chromatography (TLC) was performed on Merck precoated 60F254 plates. 
Reactions were monitored by TLC on silica gel, with detection by Uv light ( = 254 nm) or 
by charring with 1% permanganate solution. Flash chromatography was performed using 
Silica gel (240-400 Mesh, Merck). NMR spectra were recordered with Brucker 300 and 
400 MHz spectrometers. Chemical shifts are reported in parts per million () downfield 
from tetramethylsilane (TMS). EI mass spectra were recorded at an ionizing voltage of 6 
kEv on a VG 70-70 EQ. ESI mass spectra were recorded on FT-ICR APEXII. Specific rotations 
were measured with a P-1030-Jasco polarimeter with 10 cm optical path cells and 1 ml 
capacity (Na lamp,  = 589 nm). Microwave assisted reaction were performed with Emrys 
Creator single-mode (power range 0-400 W from magnetron at 2.45 GHz). 
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Synthesis of 3 
 
 
 
To a solution of 4-hydroxybenzaldehyde (2.005 g, 16.377 mmol) in acetone (100 mL) 
allybromide (3.950 g, 32.653 mmol), K2CO3 (4.502 g, 32.574 mmol) and KI (0.273 g, 1.644 
mmol) are added and the reaction mixture is stirred at room temperature for 3h. Brine 
(70 mL) is added and extracted with AcOEt (5x15 mL). The organic layers are dried over 
Na2SO4 and the solvent is removed under reduced pressure to obtain 3 as a yellow oil 
(2.660 g, Yield: > 90%) without any further purification. 
1H-NMR (CDCl3, 300 MHz): δ(ppm) = 9.98 (s, 1H), 7.82 (d, J=8.8 Hz, 2H), 7.01 (d, J=8.8 Hz, 
2H), 6.09-5.99 (m, 1H), 5.45-5.43 (m, 1H), 5.35-5.31 (m, 1H), 4.61 (dt, J=5.2, 1.4 Hz, 2H).  
13C-NMR (CDCl3, 100 MHz): δ (ppm) = 190.6, 163.6, 132.3, 131.9, 130.1, 118.2, 115.0, 
69.0.  
ESI-MS: m/z 185 (M + Na)+.  
IR (neat): 3076, 2925, 2837, 1686, 1596, 1575, 1507 cm-1.  
Anal. Calcd for C10H10O2: C, 74.06; H, 6.21. Found: C, 73.95; H, 6.32. 
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Synthesis of 4 
 
 
 
To a solution of 3 (0.308 g, 1.899 mmol) in EtOH (15 mL) at 0°C NaBH4 (0.144 g, 3.798 
mmol) is added and the reaction mixture is stirred at 0°C for 2.5 h. The solvent is the 
removed under reduced pressure, H2O (20 mL) is added and extracted with CH2Cl2 (5x10 
mL). The organic layers are dried over Na2SO4 and the solvent is removed under reduced 
pressure to obtain 4 as a yellow oil (0.303 g, Yield: > 90%) without any further 
purification. 
1H-NMR (CDCl3, 300 MHz): δ(ppm): 7.13 (d, J=8.5 Hz, 2H), 6.89 (d, J=8.5 Hz, 2H), 5.96 (ddt, 
J=17.1, 10.5, 5.7 Hz, 1H), 5.40 (dd, J=17.1, 1.2 Hz, 1H), 5.28 (dd, J=10.5, 1.2 Hz, 1H), 4.51 
(d, J=5.7 Hz, 2H), 4.20 (s, 2H).  
13C-NMR (CDCl3 , 100 MHz): δ(ppm) = 153.4, 133.7, 128.8, 126.2, 118.3, 114.5, 69.1, 63.2. 
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Synthesis of 5 
 
 
 
To a solution of 4 (0.303 g, 1.843 mmol) in dry CH2Cl2 (26 mL) 4-nitrophenyl 
chloroformate (0.743 g, 3.694 mmol) and dry pyridine (0.582 g, 7.365 mmol) are added 
and the reaction mixture is stirred at room temperature for 18 h. The solvent is then 
removed under reduced pressure. The crude is purified by flash chromatography 
(Hex/AcOEt  9:1 ) to obtain 5 (0.449 g, Yield: 72%). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm): 8.27 (d, J=9.4 Hz, 2H), 7.40 (d, J=9.4 Hz, 2H), 7.36 (d, 
J=8.5 Hz, 2H), 6.93 (d, J=8.5 Hz, 2H), 6.09-6.01 (m, 1H), 5.40 (dd, J=17.1, 1.2 Hz, 1H), 5.28 
(dd, J=10.5, 1.2 Hz, 1H), 5.22 (s, 2H), 4.51-4.47 (m, 2H).  
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Synthesis of 6 
 
 
 
Compound 3 (3.492 g, 21.011 mmol) is exposed to microwave radiation in a microwave 
oven at 190°C for 30 minutes. The crude is purified by flash chromatography (Hex/AcOEt 
8:2 ) to obtain 6 (2.657 g, Yield: 78%). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm): 9.85 (s, 1H), 7.69-7.62 (m, 2H), 6.92 (d, J=8.5 Hz, 1H), 
6.01-5.96 (m, 1H), 5.25-5.19 (m, 2H), 3.49-3.41 (m, 2H). 
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Synthesis of 7 
 
 
 
To a mixture of Ac2O/Pyridine 1:1 (40 mL) 6 (2.003 g, 12.301 mmol) is added and the 
reaction mixture is stirred at room temperature for 2 h. At 0°C solid NaHCO3 is added. The 
reaction mixture is extracted with AcOEt (3x20 mL) and organic layers are washed with 
H2O. The organic layers are dried over Na2SO4 and the solvent is removed under reduced 
pressure. The crude is purified by flash chromatography (Hex/AcOEt 85:15) to obtain 7 
(2.302 g, Yield: 80%). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm): 9.85 (s, 1H), 7.77-7.73 (m, 2H), 7.23 (d, J=11.1 Hz, 1H), 
5.94-5.84 (m, 1H), 5.14-5.09 (m, 2H), 3.38-3.34 (m, 2H), 2.33 (s, 3H). 
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Synthesis of 8 
 
 
 
To a solution of 7 (0.203 g, 0.984 mmol) in EtOH (10 mL) at 0°C NaBH4 (0.074 g, 1.965 
mmol) is added and the reaction mixture is stirred at 0°C for 30 minutes. The solvent is 
the removed under reduced pressure, H2O (20 mL) is added and extracted with CH2Cl2 
(5x10 mL). The organic layers are dried over Na2SO4 and the solvent is removed under 
reduced pressure. The crude is purified by flash chromatography (CH2Cl2/MeOH 98:2) to 
obtain 8 (0.151 g, Yield: 75%). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm): 7.22-7.18 (m, 2H), 7.02 (d, J=8.5 Hz, 1H), 5.91-5.81 (m, 
1H), 5.11-5.03 (m, 2H), 4.65 (s, 2H), 3.32-3.28 (m, 2H), 2.31 (s, 3H). 
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Synthesis of 9 
 
 
 
To a solution of 8 (1.194 g, 5.791 mmol) in dry CH2Cl2 (80 mL) 4-nitrophenyl 
chloroformate (2.343 g, 11.594 mmol) and dry pyridine (0.917 g, 11.594 mmol) are added 
and the reaction mixture is stirred at room temperature for 36 h. The solvent is then 
removed under reduced pressure. The crude is purified by flash chromatography 
(Hex/AcOEt  8:2 ) to obtain 9 (2.101 g, Yield: 90 %). 
 
1H-NMR (300 MHz, CDCl3): δ(ppm): 8.27 (d, J=9.4 Hz, 2H), 7.37 (d, J=9.4 Hz, 2H), 7.32-7.28 
(m, 2H), 7.07 (d, J=8.8, 1H), 5.93-5.89 (m, 1H), 5.25 (s, 2H), 5.11-5.03 (m, 2H), 3.32-3.28 
(m, 2H), 2.31 (s, 3H). 
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Synthesis of 10 
 
 
 
To a solution of 9 (1.106 g, 5.654 mmol) in dry THF (50 mL) BH3.THF (7.771 mL, 3.885 
mmol) is added and the reaction mixture is stirred at rt for 22 h. At 0°C H2O2 (0.166 mL, 
7.079 mmol) is added and the reaction mixture is stirred at rt for 30 minutes. Solid NaCl 
and H2O (50 mL) are added and extracted with Et2O (3x40 mL). The organic layers are 
washed with brine, dried over Na2SO4 and the solvent is removed under reduced 
pressure. The crude is purified by flash chromatography (Hex/AcOEt 1:1) to obtain 10 
(1.221 g, Yield: 50 %). 
 
1H-NMR (CDCl3, 300 MHz): δ(ppm): 8.27 (d, J=9.4 Hz, 2H), 7.37 (d, J=9.4 Hz, 2H), 7.33-7.28 
(m, 2H), 7.07 (d, J=8.8, 1H), 5.25 (s, 2H), 3.64 (t, J=6.1, 2H), 2.65 (t, J=7.1, 2H), 2.31 (s, 3H), 
1.89-1.80 (m, 2H). 
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Synthesis of 11a 
 
 
 
To a solution of (-)-thiocolchicine (500 mg, 1.205 mmol) in MeOH (20 mL), HCl 2N (9.650 
mL, 19.312 mmol) is added and the reaction mixture is stirred at reflux at 90 °C for 57 h. 
The solvent is removed under reduced pressure. H2O (20 mL) is added and extracted with 
CH2Cl2 (3x15 mL). The aqueous layer is neutralized with NaOH, extracted with CH2CI2. The 
organic layers are washed with brine and dried over Na2SO4. The solvent is removed 
under reduced pressure. The crude is purified by flash chromatography (CH2Cl2/MeOH 
9:1) to obtain 11a (0.387 g, Yield: 86 %). 
 
1H-NMR (CDCl3, 300 MHz, detected signals):  (ppm): 9.52 (bs, 2H), 7.58 (s, 1H), 7.19 (d, 
J=10.5 Hz, 1H), 7.03 (d, J=10.5 Hz, 1H), 6.54 (s, 1H), 4.25-4.20 (m, 1H),  3.91 (s, 6H), 3.66 
(s, 3H), 2.43 (s, 3H),  2.41-2.28 (m, 4H).  
 
Anal. calcd for (C20H23NO4S): C, 64.32, H, 6.21, N, 3.75, S, 8.58; Found: C, 64.27, H, 6.35, N, 
3.68, S, 8.47.  
 
[𝜶]𝑫
𝟐𝟎: -160.6 ° (c 0.35; MeOH). 
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Synthesis of 11b 
 
 
 
To a solution of 11a (0.303 g, 0.812 mmol) in CH2Cl2 (30 mL), N-Boc-glycine (0.312 g, 0.59 
mmol), DCC (1.009 g, 4.862 mmol) and DMAP (0.198 g, 1.624 mmol) are added. The 
reaction mixture is stirred at rt for 16 h, then filtered through Celite. The solvent is 
removed under reduced pressure. The crude is purified by flash chromatography 
(CH2Cl2/MeOH  95:5 )  to afford 11b (0.420 g, > 90%).  
 
1H-NMR (CDCl3, 300 MHz):  (ppm): 8.20 (bs, 1H), 7.54-7.47 (m, 1H), 7.44-7.40 (m, 1H), 
7.25 (s, 1H), 6.56 (s, 1H), 4.72-4.65 (m, 1H), 3.93-3.71 (m, 8H), 3.63 (s, 3H), 2.54-2.39 (m, 
5H), 2.13-1.94 (m, 2H), 1.45 (s, 9H).  
 
13C-NMR (CDCl3, 100 MHz, detected signals):  (ppm):  182.3, 169.6, 158.2, 156.3, 154.5, 
151.0, 141.8, 139.1, 135.5, 131.4, 128.1, 107.2, 80.6, 61.5, 61.3, 56.1, 52.1, 45.0, 36.4, 
29.9, 28.3, 15.3.  
 
Anal. Calcd for C27H34N2O7S: C, 61.11; H, 6.46; N, 5.28. Found: C, 61.14; H, 6.41; N, 5.30.  
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Synthesis of 11 
 
 
 
To a solution of 11b (0.420 g, 0.812 mmol) in dry CH2Cl2 (20 mL) at 0°C TFA (2.418 g, 
21.085 mmol) is added and the reaction mixture is stirred at rt for 1 h. The solvent is 
removed under reduced pressure to obtain 11 (0.430 g, Yield: > 95%) without any further 
purification.  
 
1H-NMR (CDCl3, 300 MHz, detected signals):  (ppm): 10.33 (bs, 1H), 8.14 (d, J=5.4 Hz, 
1H), 7.87 (d, J=11.4 Hz, 1H), 7.69 (d, J=11.4 Hz, 1H), 6.62 (s, 1H), 4.59-4.65 (m, 1H), 4.13-
4.07 (m, 3H), 3.93 (s, 6H), 3.59 (s, 3H), 3.48-3.44 (m, 2H), 2.43-2.34 (m, 1H), 2.25 (s, 3H), 
2.12-2.01 (m, 1H), 1.94-1.73 (m, 2H).  
 
13C-NMR (CDCl3, 100 MHz, detected signals):  (ppm): 182.3, 158.2, 156.3, 154.5, 151.0, 
141.8, 139.1, 135.5, 131.4, 128.1, 107.2, 61.5, 61.3, 56.1, 52.1, 45.0, 36.4, 29.9, 15.3. 
  
Anal. Calcd for C22H26N2O5S: C, 61.38; H, 6.09; N, 6.51. Found: C, 61.42; H, 6.08; N, 6.48. 
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Synthesis of 12 
 
 
 
To a solution of 11 (0.438 g, 0.812 mmol) in dry CH2Cl2 (10 mL) DMAP (0.247 g, 2.015 
mmol) and a solution of 10 (0.315 g, 0.812 mmol) are added and the reaction mixture is 
stirred at reflux at 40°C for 3 h. The solvent is removed under reduced pressure. The 
crude is purified by flash chromatography (CH2Cl2/MeOH 95:5) to afford 12 (0.399 g, 
72%).  
 
1H-NMR (CDCl3, 300 MHz, detected signals):  (ppm): 8.14-8.01 (m, 1H), 7.59-7.87 (m, 
2H), 7.30 (s, 1H), 7.16-7.06 (m, 1H), 6.98-6.92 (m, 1H), 6.53 (s, 1H), 5.01 (s, 2H), 4.68-4.62 
(m, 1H), 3.93-3.87 (m, 8H), 3.62 (s, 3H), 3.59-3.54 (m, 2H), 2.61-2.54 (m, 4H), 2.41 (s, 3H), 
2.29 (s, 3H), 1.91-1.76 (m, 4H). 
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Synthesis of 13a 
 
 
 
To a solution of sebacic acid (0.255 g, 1.263 mmol) in dry THF (20 mL) HATU (0.527 g, 
1.386 mmol) and DIPEA (0.326 g, 2.523 mmol) are added and the reaction mixture is 
stirred for 30 minutes. Then 4-(1,2-diphenylbut-1-en-1-yl)aniline (0.378 g, 1.265 mmol) is 
added and the reaction mixture is stirred at rt overnight. The solvent is removed under 
reduced pressure, AcOEt is added and it is washed with water and brine. The organic layer 
is then dried over Na2SO4 and concentrated under reduced pressure. The crude is purified 
by flash chromatography (AcOEt/Hex 4:6) to obtain pure 13a (0.476 g, Yield: 78%).  
 
1H-NMR (CDCl3, 300 MHz): δ(ppm)= 7.33-7.02 (m, 12H), 6.80 (d, J=7.8, 2H), 4.78 (bs, 1H), 
2.43  (q,  J = 7.6  Hz, 2H), 2.30 ( t, J=7.7  Hz, 2H), 2.25 (t, J=7.5 Hz, 2H), 1.75-1.55 (m, 4H), 
1.40-1.25 (m, 8H), 0.92  (t,  J =7.7  Hz).  
 
13C-NMR (CDCl3, 75 MHz): δ(ppm)= 175.3, 174.6, 145.1, 143.2, 143.1, 141.3, 139.7, 135.4, 
131.9, 129.6, 129.4, 128.2, 127.7, 127.3, 126.3, 116.1, 37.58, 34.98, 31.80, 30.81, 26.96, 
26.22, 13.60. 
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Synthesis of 13b 
 
 
 
To a solution of 4,4'-dithiobutyric acid (0.228 g, 0.958 mmol) in dry THF (15 mL) HATU 
(0.401 g, 1.054 mmol) and DIPEA (0.248 g, 1.921 mmol) are added and the reaction 
mixture is stirred for 30 minutes. Then 4-(1,2-diphenylbut-1-en-1-yl)aniline (0.827 g, 
0.958 mmol) is added and the reaction mixture is stirred at rt overnight. Then, the solvent 
is removed under reduced pressure. H2O (20 mL) is added, acidified with HCl and 
extracted with CH2Cl2 (3x15 mL). The combined organic layers are dried over Na2SO4 and 
evaporated under reduced pressure.  The crude is  purified  by  flash chromatography 
(Hex/EtOAc 6:4 + 1% of glacial acetic acid) to provide 13b  (0.289  g,  Yield: 58%). 
 
1H-NMR (CDCl3, 300 MHz) δ(ppm): 7.30-7.05 (m, 12H), 6.80 (d, J=8.5 Hz, 2H), 2.75 (q, 
J=7.6 Hz, 2H), 2.45 (t,  J=7.5 Hz, 4H), 2.07-1.96  (m, 4H), 1.35-1.25  (m, 4H), 0.95  (t,  J=7.7 
Hz, 3H). 
  
Experimental Procedures
 
156 
Synthesis of 1 
 
  
 
To a suspension of 13a (0.106 g, 0.221 mmol) in dry CH2Cl2 (5 mL) EDC.HCl (0.050 g, 0.262 
mmol), DMAP (0.019 g, 0.154 mmol) are added and the reaction mixture is stirred for 30 
minutes. Then 12 (0.150 g, 0.221 mmol) is added and the reaction mixture is stirred at rt 
for 48 h. The solvent is removed under reduced pressure. The crude is purified by flash 
chromatography (CH2Cl2/MeOH 98:2) to afford 1 (0.063 g, 25%).  
 
1H-NMR (CDCl3, 300 MHz, detected signals):  (ppm): 7.47-6.79 (m, 20H), 6.53 (s, 1H), 
5.01 (s, 2H), 4.68-4.62 (m, 1H), 4.07-4.02 (m, 2H), 3.93-3.87 (m, 8H), 3.62 (s, 3H), 2.61-
2.42 (m, 6H), 2.39 (s, 3H), 2.23-2.17 (m, 7H), 1.89-1.85 (m, 2H), 1.70-1.59 (m, 6H), 1.36-
1.22 (m, 8H), 0.92  (t,  J =7.7 Hz, 3H).   
 
13C-NMR (400 MHz, CDCl3, detected signals):  (ppm):  172.02, 170.08, 169.49, 159.11, 
157.33, 154.38, 151.84, 149.39, 144.14, 143.69, 142.86, 142.71, 142.36, 139.94, 139.45, 
139.10, 138.84, 137.38, 136.49, 135.60, 135.00, 134.87, 133.82, 131.98, 131.46, 130.70, 
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130.34, 130.14, 129.11, 128.79, 128.56, 128.44, 127.99, 127.89, 127.44, 127.28, 126.84, 
126.39, 126.27, 123.15, 120.10, 119.24, 115.24, 114.73, 108.13, 67.20, 64.25, 62.23, 
62.06, 56.80, 52.87, 45.21, 38.30, 37.20, 34.99, 34.49, 32.59, 30.54, 30.35, 29.73, 29.65, 
29.42, 27.42, 26.16. 
 
ESI-MS: m/z 1168.8 [M+Na]+. 
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Synthesis of 2 
 
 
 
To a suspension of 13b (0.114 g, 0.221 mmol) in dry CH2Cl2 (5 mL) EDC.HCl (0.050 g, 0.262 
mmol), DMAP (0.019 g, 0.154 mmol) are added and the reaction mixture is stirred for 30 
minutes. Then 12 (0.150 g, 0.221 mmol) is added and the reaction mixture is stirred at rt 
for 48 h. The solvent is removed under reduced pressure. The crude is purified by flash 
chromatography (CH2Cl2/MeOH  95:5 )  to afford 2 (0.184 g, 71%).  
 
1H-NMR (300 MHz, CDCl3, detected signals):  (ppm): 7.47-6.75 (m, 20H), 6.53 (s, 1H), 
4.95 (s, 2H), 4.68-4.62 (m, 1H), 4.07-4.02 (m, 2H), 3.93-3.87 (m, 8H), 3.62 (s, 3H), 2.69-
2.25 (m, 20H), 2.09-1.82 (m, 8H), 0.92  (t,  J=7.7 Hz, 3H).  
 
13C-NMR (400 MHz, CDCl3, detected signals):  (ppm):  182.91, 173.76, 171.08, 170.09, 
169.61, 159.07, 157.34, 154.36, 151.84, 149.35, 144.13, 142.84, 142.73, 142.32, 139.50, 
139.09, 138.83, 136.51, 135.52, 135.06, 134.93, 133.68, 131.96, 131.45, 130.67, 130.33, 
130.13, 129.19, 128.80, 128.57, 127.83, 127.28, 126.85, 126.29, 123.12, 120.13, 119.26, 
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114.73, 108.14, 67.12, 64.52, 62.23, 62.06, 56.80, 52.90, 45.12, 38.65, 38.35, 37.09, 
36.07, 33.26, 30.58, 30.35, 29.73, 29.29, 27.38, 25.14, 24.97, 21.59, 15.80, 14.20. 
 
ESI-MS: m/z 1204.7 [M+Na]+. 
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Lipase-incubation of 1 
 
 
 
To a solution of 1 in DMSO : Posphate Buffer 20 mM pH7 (1 mg/mL), n-BuOH (0.010 mL, 
0.1091 mmol) and the desired enzyme (PS @Celite, 10 mg) preparation are added. The 
mixture is incubated at 45°C for 6 hours, then half the reacting media is extracted with 
AcOEt. The organic layer is dried over Na2SO4, evaporated in vacuo and dissolved again in 
CH3CN/ MeOH (2:1) in order to be analysed by reversed-phase HPLC (Kinetex 5µ EVO C18 
100Å, λ= 256 nm, flow= 0.3 mL/min, A= H2O milliQ + 0.01 TFA, B= CH3CN + 0.01 TFA, 
gradient: t0 A= 90%, 30 min A=20%, 35 min A=0%,). 
Overnight reaction with PS @Celite gave the 85% of 1 hydrolysis on the bases of the total 
products area, in this case deacetylthiocolchicine and 4-(1,2-diphenylbut-1-en-1-
yl)aniline. 
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Lipase-incubation of 2 
 
 
 
To a solution of 2 in DMSO : Posphate Buffer 20 mM pH7 (1 mg/mL), n-BuOH (0.010 mL, 
0.1091 mmol) and the desired enzyme (PPL, Porcine Pancreatic lipase type II, 10 mg) 
preparation are added. The mixture is incubated at 45°C for 6 hours, then half the 
reacting media is extracted with AcOEt. The organic layer is dried over Na2SO4, 
evaporated in vacuo and dissolved again in CH3CN/ MeOH (2:1) in order to be analysed by 
reversed-phase HPLC (Kinetex 5µ EVO C18 100Å, λ= 256 nm, flow= 0.3 mL/min, A= H2O 
milliQ + 0.01 TFA, B= CH3CN + 0.01 TFA, gradient: t0 A= 90%, 30 min A=20%, 35 min 
A=0%,). 
Overnight reaction with PPL gave the 85% of 2 hydrolysis on the bases of the total 
products area, in this case deacetylthiocolchicine and 4-(1,2-diphenylbut-1-en-1-
yl)aniline. 
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In this chapter, a different class of self-assembling conjugates is described. These 
compounds are characterized by a homodimeric structure: two molecule of the same 
drug are connected through a disulphide-containing linker (Figure 48).  
 
 
Figure 48. General structure of the homodimeric conjugates. 
 
The publication of a recent paper regarding the spontaneous formation of nanoparticles 
by self-assembly of homodimeric compounds, which are not characterized by the 
presence of a self-assembly inducer tail,177,178 moved us to reconsider the synthesis of 
disulphide-containing bivalent compounds, previously reported by our research group 
and able to release active drugs inside tumor cells.179 
As a linker, we selected 4,4′-dithiodibutyric acid based on our previous studies, and we 
used paclitaxel (Chapter 2), podophyllotoxyn (Chapter 3), epothilone A and camptothecin 
as anticancer drugs. 
 
Epothilone A 
 
The epothilones are a class of natural cytotoxic macrolides first isolated by Gerhard Höfle 
of the National Biotechnology Research Institute in Braunschweig, Germany from a 
cultured strain of the myxobacterium Sorangium cellulosum in the late 1980s.180,181 The 
chief components of the fermentation process are epothilone A and B, with epothilone C 
and D found in smaller amounts. Trace amounts of other epothilones are also detected 
(Figure 49). 
The structures of epothilones A and B include a 16-membered macrocyclic lactone that 
differs only in the presence of a hydrogen or methyl group, while epothilones C and D lack 
of the epoxide ring. 
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Figure 49. Epothilones and Sorangium Cellulosum. 
Although the epothilones can already be made by fermentation, several research groups 
have reported methods for their total synthesis.182 
Epothilones, like paclitaxel, induce tubulins to form microtubules at low temperatures 
and without guanosine triphosphate or microtubule-associated proteins.183 
Epothilones exhibit kinetics similar to those of paclitaxel in inducing tubulin 
polymerization into microtubules in vitro (filtration, light scattering, sedimentation, and 
electron microscopy) and in producing enhanced microtubule stability and bundling in 
cultured cells. Furthermore, these 16-membered macrolides are competitive inhibitors of 
paclitaxel binding, exhibiting a 50% inhibitory concentration almost identical to that of 
paclitaxel in displacement competition assays. 
Epothilone A has been shown to be 2000 to 5000 times more active than paclitaxel in 
vitro against P-glycoprotein– expressing MDR tumors and cell lines as well as tumors 
resistant to the taxanes based on tubulin mutations.  
Unfortunately, epothilones showed to be unstable in mouse plasma, resulting in 
metabolites with a mass 18 units higher than the parent drugs, and it was subsequently 
demonstrated that administration of the esterase inhibitor bis(4-nitrophenyl)-phosphate 
produced an active result in the A2780 ovarian carcinoma tumor model.  
For these reasons many efforts have been made in order to synthetize epothilone 
analogues  with the goal of improving metabolic stability. 
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Camptothecin 
 
Camptothecin (CPT) is a pentacyclic quinoline-containing alkaloid isolated in 1958 from 
Camptotheca Acuminata184 (Figure 50) that acts as a selective inhibitor of the nuclear 
enzyme Topoisomerase I (TOP I). 
 
 
         
 
Figure 50. Camptothecin and Camptotheca Acuminata. 
 
Unfortunately, therapeutic application of unmodified CPT is hindered by very low water 
solubility in aqueous medium, high toxicity and rapid inactivation through lacone 
hydrolysis in vivo. 
To overcome the solubility and stability issues, various derivatives have been developed. 
Although a number of small and large molecule compounds are currently in clinical trials, 
only two CPT derivatives, irinotecan and topotecan, are approved for clinical use (Figure 
51).185 
 
 
Figure 51. Structures of camptothecin analogues. 
 
Irinotecan is currently used for metastatic colorectal cancer, while topotecan has been 
approved for ovarian cancer, cervical cancer and small-cell lung cancer.  
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These derivatives employ tertiary amine cations to improve solubility and subsequently 
improve lactone stability.  
 
Substituted camptothecins 
 
To summarize the SAR studies, the A and B rings are the most tolerant to modification 
with substitutions at positions 7, 9, 10, and 11 improving or retaining activity.186 
Interestingly, von Hoff has provided evidence that substitutions that increase hydrogen 
bonding at the 7-position improve binding to TOP I, thus increasing activity over CPT.187  
On the other hand, altering the C and D rings or substituting positions 12 and 14 
inactivates the molecules. 
Finally, the E-ring lactone is necessary for activity by binding to TOP I: Hydrolysis or 
removal of the lactone leads to loss of all activity. The equilibrium between the closed, 
active lactone and the open, inactive carboxylate form is influenced by both the affinity of 
the carboxylate for human serum albumin and the local pH in vivo (Figure 52).  
 
 
Figure 52. Lactone hydrolysis. 
 
Since it is the site where binding to TOP I occurs, the E ring tolerates only minor 
modifications without dramatic, negative effects. For example, enlargement of the ring to 
form the betahydroxy lactone improves stability and drug activity. Interestingly, 
modification of the C20 hydroxyl group through alkylation or acylation has been shown to 
stabilize the lactone. Acylation is the favoured method for linking CPT covalently to 
macromolecules. 
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In addition, different kinds of CPT formulations have been prepared in order to 
accomplish CPT delivery to tumour cells by passive targeting, including micelles,188 
liposomes,189 chitosan nanoparticles190 and hydrogels.191 
 
Synthesis of the conjugates 
 
The general reaction for the synthesis of the homodimeric conjugates is reported in 
Scheme 18. 
 
 
Scheme 18. General reaction for the synthesis of homodimeric compounds 1-4. 
 
All the conjugates were synthetized through a condensation reaction mediated by a 
condensing agent in the presence of DMAP. As condensing agent, it was used EDC∙HCl for 
the drugs podophyllotoxyn, paclitaxel and camptothecin and DCC in the case of 
epothilone A (Table 14). 
Drug Condensing agent Reaction time (h) Yield (%) 
Podophyllotoxyn (1) EDC∙HCl 72 85 
Paclitaxel (2) EDC∙HCl 96 29 
Epothilone-A (3) DCC 96 16 
Camptothecin (4) EDC∙HCl 96 27 
Table 14. Reaction conditions and yields for the synthesis of dimers 1-4. 
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1H-NMR analysis of the isolated products confirmed the formation of the ester bond: for 
the derivatives of podophyllotoxyn, paclitaxel and epothilone A we were able to observe 
a  downshift of the hydrogen on the carbon bearing the hydroxylic functionalized group 
(Table 15). 
For the homodimeric conjugate of camptothecin, the 1H-NMR was not crucial for the 
product characterization because the derivatized hydroxylic group is on a quaternary 
carbon.  
Drug Signal 
Parental drug 
(ppm) 
Product 
(ppm) 
Podophyllotoxin  EDC∙HCl 4.61 5.85 
Paclitaxel H-2’ 4.78 5.51 
Epothilone-A H-7 3.80 5.44-5.37 
Table 15. 1H-NMR signal shift. 
The definitive confirmation of the homodimeric structure of the products was achieved 
using mass spettrometry analysis. For conjugates 1-3 it was verified the presence of two 
molecule of the drugs bound to the 4,4′-dithiodibutyric acid, but for conjugate 4 it was 
demonstrated the formation of the product shown below (Figure 53). 
 
 
 
Figure 53. Structure of the obtained product. 
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Nanoparticles characterization 
 
Next, the ability of the obtained compounds 1-3 to form NPs was investigated. Three 
different nanosuspensions were prepared by a dropwise addition of an organic solution 
of the compounds to ultrapure water and by the subsequent removal of the organic 
solvent under reduced pressure. All the conjugates seemed to self-assemble, and the 
resulting homogeneous suspensions were characterized by DLS. 
DLS measurements (Table 16) gave the confirmation of the success of the process: 
compounds 1, 2 and 3 were able to give monodisperse suspensions of NPs, with 
hydrodynamic diameters in the range of  200-300 nm.  
Zeta potential values were negative for both the nanoassemblies suggesting that the 
electrostatic repulsion contributes to the colloidal stability of the suspension.  
Compound Mean Diameter (nm) Z potential (mV) 
1 298.5 ± 11.21 -14.7 ± 3.16 
2 198.1 ± 6.747 -32.1 ± 0.709 
3 208.7 ± 2.205 -21.1 ± 0.635 
Table 16.  Nanoparticles characterization. 
 
The next step is the biological evaluation of the activity on different types of cell lines of 
these conjugates and of the corresponding nanoparticles.  
 
 
  
  
  
 
 
 
 
Experimental Procedures 
  
  
 
Experimental Procedures
 
175 
General 
 
Thin-layer chromatography (TLC) was performed on Merck precoated 60F254 plates. 
Reactions were monitored by TLC on silica gel, with detection by Uv light ( = 254 nm) or 
by charring with 1% permanganate solution. Flash chromatography was performed using 
Silica gel (240-400 Mesh, Merck). NMR spectra were recordered with Brucker 300 and 
400 MHz spectrometers. Chemical shifts are reported in parts per million () downfield 
from tetramethylsilane (TMS). EI mass spectra were recorded at an ionizing voltage of 6 
kEv on a VG 70-70 EQ. ESI mass spectra were recorded on FT-ICR APEXII. Specific rotations 
were measured with a P-1030-Jasco polarimeter with 10 cm optical path cells and 1 ml 
capacity (Na lamp,  = 589 nm). Microwave assisted reaction were performed with Emrys 
Creator single-mode (power range 0-400 W from magnetron at 2.45 GHz). 
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Synthesis of 1 
 
 
 
To a solution of 4,4′-dithiodibutyric acid (0.009 g, 0.0.041 mmol) in dry CH2Cl2 (3 mL) 
EDC.HCl (0.016 g, 0.082 mmol), DMAP (0.010 g, 0.082 mmol) and podophyllotoxin (0.050 
g, 0.082 mmol) are added and the reaction mixture is stirred for 72 h. The solvent is 
removed under reduced pressure. The crude is purified by flash chromatography 
(CH2Cl2/MeOH  96:4 )  to afford 1 (0.036 g, 85%). 
 
1H-NMR (CDCl3, 400 MHz): δ (ppm): 6.78 (s, 2H), 6.53 (s, 2H), 6.39 (s, 4H), 5.91 (d, J=4.2 
Hz, 4H), 5.88 (d, J=8.1 Hz, 2H), 4.58 (d, J=3.6 Hz, 2H), 4.53-4.41 (m, 2H), 4.15-4.04 (m, 2H), 
3.80 (s, 6H), 3.75 (s, 12H), 2.83-2.75 (m, 4H), 2.70-2.62 (m, 4H), 2.55-2.40 (m, 4H), 2.07-
1.98 (m, 4H). 
 
13C-NMR (CDCl3, 400 MHz): δ(ppm): 173.6, 173.4, 152.6, 148.2, 147.6, 137.1, 134.8, 132.4, 
128.2, 109.8, 108.1, 107.0, 101.7, 73.8, 71.3, 60.7, 56.2, 45.5, 43.7, 38.7, 37.5, 32.5, 24.0. 
 
ESI-MS: m/z 1053.46 [M + Na+]+. 
 
[𝜶𝑫
𝟐𝟐]= -89.11 (c = 0.365, CHCl3).  
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Synthesis of 2 
 
 
 
To a solution of 4,4′-dithiodibutyric acid (0.007 g, 0.0.029 mmol) in dry CH2Cl2 (2 mL) 
EDC.HCl (0.007 g, 0.058 mmol), DMAP (0.011 g, 0.058 mmol) and paclitaxel (0.050 g, 
0.058 mmol) are added and the reaction mixture is stirred for 96 h. The solvent is 
removed under reduced pressure. The crude is purified by flash chromatography 
(CH2Cl2/MeOH  95:5 )  to afford 2 (0.016 g, 29%). 
 
1H-NMR (CDCl3, 400M Hz): δ (ppm): 8.13 (d, J=7.9 Hz, 4H), 7.74 (d, J=7.8 Hz, 4H), 7.61 (t, 
J=7.8 Hz, 2H), 7.53-7.40 (m, 18H), 7.35 (s, 2H), 6.90 (d, J=6.7 Hz, 2H), 6.27 (s, 2H), 6.23-
6.17 (m, 2H), 6.00-5.89 (m, 2H), 5.72 (d, J=6.9 Hz, 2H), 5.51 (d, J=3 Hz, 2H), 4.95 (d, J=8.4 
Hz, 2H), 4.45-4.34 (m, 2H), 4.30 (d, J=14.4 Hz, 2H), 4.19 (d, J=14.4 Hz, 2H), 3.81 (d, J=6.9 
Hz, 2H), 2.65-2.50 (m, 10H), 2.43 (s, 6H), 2.35-2.28 (m, 4H), 2.23 (s, 6H), 2.07-1.71(m, 
18H), 1.24 (s, 6H), 1.14 (s, 6H). 
 
13C-NMR (CDCl3, 400 MHz): δ(ppm): 204.43, 172.63, 171.89, 170.49, 168.72, 167.72, 
143.32, 137.60, 134.36, 133.54, 132.70, 132.24, 130.91, 130.58, 130.40, 129.78, 129.42, 
Experimental Procedures
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129.19, 128.48, 127.78, 127.20, 85.11, 81.77, 79.85, 76.26, 75.91, 74.74, 73.51, 72.53, 
70.12, 59.20, 53.44, 46.29, 43.86, 37.59, 36.23, 32.60, 30.36, 27.48, 24.51, 23.38, 22.76, 
21.48, 15.48, 10.28. 
 
ESI-MS: m/z 1910.17 [M + Na+]+. 
 
 [𝜶𝑫
𝟐𝟐]= -40.5077(c=0.65,CHCl3). 
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Synthesis of 3 
 
 
To a solution of 4,4′-dithiodibutyric acid (0.007 g, 0.0.030 mmol) in dry CH2Cl2 (2 mL) DCC 
(0.012 g, 0.061 mmol), DMAP (0.007 g, 0.061 mmol) and epothilone A (0.030 g, 0.061 
mmol) are added and the reaction mixture is stirred for 96 h. The solvent is removed 
under reduced pressure. The crude is purified by flash chromatography (Hex/AcOEt  1:1)  
to afford 3 (0.006 g, 16%). 
 
1H-NMR (400 MHz, CDCl3): δ(ppm): 7.05 (s, 2H), 6.63 (s, 2H), 5.51 (dd, J=2.3, 6.8 Hz, 2H), 
5.38 (dd, J1=1.9, 8.7 Hz, 2H), 4.14-4.11 (m, 2H), 3.42-3.38 (m, 2H), 3.10-3.06(m, 2H), 2.93-
2.90 (m, 2H), 2.78 (t, J=7.0 Hz, 4H), 2.72 (s, 6H), 2.61-2.54 (m, 4H), 2.50 (t, J=7.3 Hz, 4H), 
2.15 (s, 6H), 2.15-2.10 (m, 2H), 2.06 (t, J=7.1 Hz, 4H), 1.99-1.96 (m, 2H), 1.80-1.76 (m, 2H), 
1.65-1.55 (m, 8H), 1.38 (s, 6H), 1.33-1.18 (m, 4H), 1.13 (s, 6H), 1.08 (d, J=6.9 Hz, 6H), 0.94 
(d, J=6.8 Hz, 6H). 
 
13C-NMR (400 MHz, CDCl3): δ(ppm): 216.2, 172.3, 170.4, 164.3, 152.2, 136.6, 120.0, 116.3, 
78.4, 76.1, 73.9, 57.3, 53.8, 52.3, 43.7, 38.5, 38.0, 34.5, 32.6, 31.8, 29.4, 26.3, 24.4, 24.1, 
22.1, 20.4, 19.0, 17.5, 15.5, 15.3. 
 
ESI-MS: m/z 1211.50[M + Na+]+. 
 
[𝜶𝑫
𝟐𝟓]= -3.8 (c =0.554, CHCl3).  
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Synthesis of 4 
 
 
 
 
To a solution of 4,4′-dithiodibutyric acid (0.017 g, 0.0.072 mmol) in dry CH2Cl2 (3 mL) 
EDC.HCl (0.027 g, 0.143 mmol), DMAP (0.017 g, 0.143 mmol) and camptothecin (0.050 g, 
0.143 mmol) are added and the reaction mixture is stirred for 96 h. The solvent is 
removed under reduced pressure. The crude is purified by flash chromatography 
(CH2Cl2/MeOH 96:4) to afford 4 (0.011 g, 27%). 
 
 
1H-NMR (DMSO, 300 MHz): δ(ppm): 8.71 (s, 1H), 8.21-8.13 (m, 2H), 7.89 (t, J=9.1, 6.3 Hz, 
1H), 7.71 (t, J=9.1, 6.3 Hz, 1H), 7.03 (s, 1H), 5.51 (s, 2H), 5.27 (s, 2H), 2.76-2.66 (m, 8H), 
2.16 (q, J=6.2 Hz, 4H), 2.0-1.85 (m, 2H), 0.94 (t, J=9.3 Hz, 3H). 
 
13C-NMR (DMSO, 300 MHz): δ(ppm): 171.62, 168.7, 156.61, 152.47, 147.94, 146.09, 
145.42, 131.64, 130.46, 129.87, 128.99, 128.60, 128.06, 127.77, 118.84, 94.74, 75.91, 
66.33, 50.31, 36.93, 36.23, 32.53, 31.74, 30.22, 24.14, 23.98, 7.62. 
ESI-MS: m/z 591.28 [M + Na+]+. 
  
 
 
 
 
 
6. Conclusions 
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The project developed in my three-year Ph.D is about the functionalization of known 
anticancer compounds to form bioconjugates, characterized by an enhanced 
pharmacokinetic profile. These conjugates were synthetized in order to have self-
assembly properties and to form nanoparticles in an aqueous media. 
In this thesis, we considered all the parts of these bioconjugates:  
 the self-assembly inducer 
 the linker moiety  
 the active compound 
We first illustrated  the preparation and characterization of different squalene-
conjugates: drug-squalene conjugates of paclitaxel, cyclopamine and doxorubicin and  
fluorescent  squalene  conjugates of fluorescin and tetramethylrhodamine, that  resulted  
very  promising  for  the study  of  nanoparticles  internalization  mechanisms  by  
fluorescence spectroscopy. 
Then we applied the approach of the co-nanoprecipitation of different drug-squalene 
conjugates to obtain hetero-nanoparticles, useful for combined chemotherapy. In vitro 
and in vivo evaluation of different combinations of these conjugates gave very promising 
results demonstrating the maintenance of the cytotoxic activity of the drugs and lowering 
their toxicity.  
We next moved to the preparation of bivalent drug-conjugates, characterized by a 
cytotoxic moiety, the tamoxifen analog 4-(1,2-diphenylbut-1-en-1-yl)aniline, as self-
assembly inducer, and aloin or podophyllotoxin as cytotoxic drugs. We demonstrated the 
ability of 4-(1,2-diphenylbut-1-en-1-yl)aniline to induce the formation of nanoparticles 
and this result open the possibility to prepare a wide collection of 4-(1,2-diphenylbut-1-
en-1-yl)aniline based conjugates containing different anticancer drugs as building blocks 
and proper linkers to induce drug release after cell internalization. 
Furthermore, we studied the synthesis of a new self-immolative linker able to improve 
the drug release from the conjugates and bearing a useful anchor point for the 
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introduction of a self-assembly inducer. We employed this new linker in the preparation 
of two new conjugates containing thiocolchicine as anticancer compound and 4-(1,2-
diphenylbut-1-en-1-yl)aniline as a cytotoxic self-assembly inducer. The ability of the self-
immolative linker to release the two active part of the conjugates in the presence of a 
lipase was confirmed. We also demonstrated the ability of the conjugates to self-
assemble in nanoparticles and in the future we are planning to test the maintenance of 
the antiproliferative activity of the two building blocks in the nanoformulated systems.  
Finally we achieved the preparation of homodimeric compounds of the known anticancer 
compounds paclitaxel, podophyllotoxin and epothilone A. These conjugates were 
designed to be able to self-assemble in nanoparticles without the presence of a self-
assembly inducer tail and to release the active units thanks to the presence of a 
disulphide containing linker. We verified the ability of the homodimeric compounds to 
self-assemble in nanoparticles by DLS and the biological evaluation of the nanoassemblies 
is in progress. 
All together, the results here reported demonstrated that it is possible: 
 to obtain, by simple modification, compounds that are able to self-assemble in 
nanoparticles; 
 to obtain hetero-nanoparticles by mixing different compounds functionalized 
with the same self-assembly inducer; 
 to obtain fluorescent hetero-nanoparticles by combining drug-conjugates with a 
dye-conjugate, functionalized with the same self-assembly inducer, with the aim 
to study cell internalization mechanism. 
This approach can be applied for different types of diseases such as neurodegeneration 
and bacterial pathologies, and it could be useful for the implementation of a personalized 
medicine.
  
Acknowledgements 
 
First, I would like to thank my supervisor Prof. Daniele Passarella for the enthusiastic 
encouragement and useful advice he has provided during these three years. I would also 
like to offer a special thank to the research group for the support and help. 
Furthermore, the results obtained during this three-year project have been achieved 
thanks to a wide collaboration network including groups specialized in different research 
fields. 
Nanoparticles characterization were made in collaboration with Dott. Barbara Stella 
and Prof. Franco Dosio of Università degli Studi di Torino and NanoBioLab (Dott. 
Benedetta Riva, Dott. Veronica Collico and Prof. Davide Prosperi) of Università degli Studi 
di Milano-Bicocca.  
Biological evaluations were made in collaboration with Dott. Francesca Ricci and Dott. 
Giovanna Damia of IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Dott. Davide 
Cartelli and Prof. Graziella Cappelletti of Università degli Studi di Milano, Prof. Lisa Dalla 
Via of Università degli Studi di Padova and Dott. Panagiota A. Sotiropoulou of IRIBHM, 
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